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3. ABSTRACT 
 
The aims of this study were to characterize DNA copy number changes in benign and malignant 
thyroid tumors and parathyroid lesions using comparative genomic hybridization (CGH), and to 
study the role of cyclin D1 expression in parathyroid lesions. The CGH results were then used 
to extend the study to investigate the role of the deletion at 11q23 in parathyroid hyperplasias 
and adenomas, and particularly, PPP2R1B  as the candidate suppressor gene. The material 
consisted of 29 follicular adenomas, 20 follicular carcinomas, 26 papillary carcinomas, 13 
anaplastic carcinomas and 10 medullary carcinomas of the thyroid, and 24 samples of 
parathyroid primary hyperplasia, 16 parathyroid adenomas and five samples of  histologically 
normal parathyroid tissue. 
The CGH results from follicular adenoma and follicular carcinoma of the thyroid 
revealed differences between the two types of tumor, implying that different genes are involved 
to their development and progression. DNA copy number changes frequently occurred in 
follicular adenoma (in 14 out of 29 tumors, 48%) and were mainly gains of entire 
chromosomes, most frequently of chromosomes 5, 7, 12, 14, 17, 18 and X (in 10-34% of the 
tumors). Losses were only found in four out of the 29 adenomas (14%, two of which were 
atypical adenomas). DNA copy number changes were also extremely common in follicular 
carcinomas (in 16/20, 80%), but losses were predominant (in 13/20, 65%). Loss of chromosome 
22 was the most common genetic alteration in follicular carcinoma (n=7, 35%) and it seemed to 
be associated with the widely invasive type. In two of the four adenomas showing losses, the 
lost chromosome was also 22 (one of them was an atypical adenoma). These CGH results, 
therefore, suggest that some follicular adenomas, including atypical adenoma, may progress to 
follicular carcinoma. DNA copy number changes in papillary carcinomas were rare in 
comparison to follicular carcinomas (in 3/26, 12%), and they were all gains of genetic material. 
These changes were associated with old age and the presence of lymph node metastases at 
presentation. Five (50%) of the 10 medullary carcinomas of the thyroid displayed DNA copy 
number changes. Deletions were detected in four of them, and the loss of chromosome 22 in 
two of them. DNA copy number changes were frequent in anaplastic thyroid carcinoma (in 
11/13, 85%), with gains of genetic material occurring more frequently than losses. The most 
common alterations were gains of genetic material at 7p, 8q, and 9q in 23% to 31% of the 
samples. The CGH results from this study suggest that DNA copy number changes vary 
according to the different histological subtypes of thyroid tumors, being frequent in follicular 
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adenomas, follicular carcinomas, anaplastic carcinomas and medullary carcinomas, but rare in 
papillary carcinomas. 
DNA copy number changes were frequent in parathyroid adenoma (in 10/16, 63%), but 
infrequent in primary parathyroid hyperplasia (in 4/24, 17%). Deletion of the entire 
chromosome 11 or part of it, with the minimal common region at 11q23, was the most frequent 
aberration and occurred in five (31%) adenomas and two samples (8%) of primary hyperplasia. 
This may imply that the region 11q23 harbors a suppressor gene that is important in the 
pathogenesis of parathyroid lesions. Overexpression of cyclin D1 was a common finding in 
parathyroid adenomas (in 6/15, 40%), whereas none of the 27 cases of primary hyperplasia or of 
the five cases of histologically normal parathyroid tissue overexpressed cyclin D1. Either DNA 
copy number loss or cyclin D1 overexpression was in present in 13 (81%) of the 16 adenomas. 
The common deletion of 11q23 in parathyroid adenoma and its occasional deletion in primary 
parathyroid hyperplasia suggests that this region may harbor a putative suppressor gene, such as 
the previously identified suppressor gene PPP2R1B. We therefore examined six cases of 
primary hyperplasia and 12 adenomas using polymerase chain reaction-based single strand 
conformation polymorphism and direct sequencing for possible mutations in the PPP2R1B 
gene. One adenoma showed a previously identified germline G-A transition (GGC-GAC) in 
codon 90. This alteration changes glycine to aspartic acid. Data from this study suggest that 
PPP2R1B alterations may not, however, be involved in the tumorigenesis of parathyroid lesions 
but it is possible that other genes in the deleted region are associated with the pathogenesis of 
parathyroid adenoma. 
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4. INTRODUCTION 
 
Follicular adenoma, the most frequently occurring benign thyroid neoplasm, is common in the 
general population (estimation 1 to 3% in United States), especially in women (Kumar et al., 
1992). Thyroid cancer is a fairly rare disease, and in most countries comprises about 1% of all 
human cancers (Parkin et al., 1992). In Finland about 300 to 350 new cases of thyroid cancer 
are diagnosed each year (Finnish Cancer Registry 2000). During the last 20-30 years, there has 
been a definite increase in the incidence rates of thyroid cancer in this country (Finnish Cancer 
Registry 2000). Thyroid nodules are two to four times more common in women than in men, 
although they are more frequently malignant in men than in women (Belfiore et al., 1992; 
Franceschi et al., 1993). At present, thyroid cancer is the fourteenth most common type of 
cancer in women in Finland (Finnish Cancer Registry 2000). The factors that correlate with the 
occurrence of thyroid cancers include increasing age, female gender, inherited disposition for 
thyroid carcinoma, and external radiation exposure (Schlumberger 1998).  
The thyroid follicular cell can give rise to four common neoplasms, the benign follicular 
adenoma, differentiated carcinomas (follicular and papillary) and undifferentiated (anaplastic) 
carcinoma. Thyroid carcinomas differ considerably in their clinical behavior, histological 
features and molecular biology. On one side of the spectrum are the papillary and follicular 
thyroid carcinomas, which usually have a favorable prognosis. They are often referred to, 
collectively, as differentiated thyroid carcinoma. At the other end of the thyroid carcinoma 
spectrum is the anaplastic carcinoma, which has a very poor prognosis and is among the most 
virulent of all human malignancies. Fortunately, anaplastic carcinoma is rare and is a disease of 
old age (Fig. 1). Medullary thyroid carcinoma is quite a rare tumor originating from the 
parafollicular C-cells, with a prognosis between those of papillary and anaplastic thyroid 
cancers. 
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Figure 1. Distribution of thyroid cancer into histologic types in different age groups in a series containing 231 
Finnish patients diagnosed in the whole country during a 5-year period. A. Males. B. Females.  
Modified from Franssila (1997). 
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Primary hyperparathyroidism (HPT) is a common endocrine disorder. Among individuals older 
than 60 years of age the incidence of HPT is estimated to be 0.03 to 0.05% (Heath et al., 1980; 
Wermers et al., 1997). However, if undiagnosed asymptomatic patients are included, the 
estimated prevalence of the disease in this age group is as high as 1-2% (Potts, 1998). Primary 
HPT can be caused by a single parathyroid adenoma (65% to 90% of cases), multiglandular 
parathyroid hyperplasia (15%), or parathyroid carcinoma (about 1%)(Berger et al., 1999). The 
histological distinction between primary parathyroid hyperplasia and adenoma is often difficult, 
as there are no specific histological features which allow a definite differentiation between the 
two (Yong et al., 1994). Primary HPT can be cured by surgery in over 90% of the cases, but 
from the surgical point of view, it is important to know whether the abnormality is a single 
adenoma, or whether there is also hyperplasia affecting the other parathyroid glands. 
The cytogenetic and molecular genetic data on the genesis of thyroid and parathyroid 
neoplasms, are limited, and the molecular changes relating to thyroid and parathyroid tumor 
progression are also poorly characterized. The aim of the present studies was to expand our 
knowledge of genetic alterations that might be associated with the progression of thyroid tumors 
and parathyroid lesions.  
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5.   REVIEW OF THE LITERATURE 
5.1.  Thyroid neoplasms 
 
Thyroid carcinomas are classified, according to the World Health Organization (WHO) 
publication “Histological Typing of Thyroid Tumours” (Hedinger et al., 1988), into four main 
histological types: papillary; follicular; anaplastic (undifferentiated); and medullary.   
Follicular adenoma is the most common thyroid tumor. Female patients typically 
outnumber male ones by about 5:1. Follicular adenoma can occur at any age, but is most 
common in middle-aged adults (Franssila 1997). It has been defined as a benign encapsulated 
tumor without vascular or capsular invasion that shows evidence of follicular cell differentiation 
(Hedinger et al., 1988). Histologically follicular adenomas may consist of follicles or they may 
have a more trabecular structure (Hedinger et al., 1988), and secondary degenerative changes 
such as hemorrhage, edema or fibrosis are sometimes present (Franssila 1997). In some 
adenomas cellular proliferation is more pronounced and the cellular architecture less regular, 
but there is still no evidence of capsular or blood vessel invasion. Such tumors have been called 
atypical adenomas (Woolner et al., 1961; Hedinger et al., 1988; Franssila 1997).  
Papillary carcinoma represents the most common type of thyroid carcinoma, accounting 
for about 70% of all the thyroid cancers (Busnardo and De Vido 2000). It occurs more 
frequently in women than in men (Franssila 1997) and in any age group, with the mean age at 
the time of initial diagnosis being approximately 40 to 45 years (Jossart and Clark 1994). This 
tumor shows evidence of follicular cell differentiation, and is characterized by the formation of 
papillae and/or a set of distinctive nuclear features (Hedinger et al., 1988). The diagnosis of 
papillary carcinoma is based on both the structure of the tumor and nuclear features in the tumor 
cells. Papillary carcinoma spreads through the lymphatics within the thyroid to the regional 
lymph nodes. It is usually strongly invasive, and regional lymph node metastases are detected in 
about one half of the cases at the time of diagnosis (Hay 1990; Grebe et al., 1996). However, 
metastases usually remain localized in the cervical lymph nodes for a long period. Tumor 
development is characterized by slow growth and good prognosis. The size of the tumor and the 
presence of distant metastases correlate with prognosis (Ain 1995; Schlumberger et al., 1986; 
Dinneen et al., 1995), but in most reports the presence of regional metastases does not correlate 
with prognosis (Franssila 1975; Carcangiu et al., 1985). Younger patients (under 40 or under 55 
years, depending on the study) seem to have a better prognosis than older ones (Akslen et al., 
1993; Lerch et al., 1997; Gilliland et al., 1997). 
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Follicular carcinoma is the second most common histological type of thyroid carcinoma, and 
accounts for 20 to 30% of all thyroid carcinomas. Patients with follicular carcinoma are 
predominantly women and are typically middle aged or elderly (Simpson et al., 1987; Gilliland 
et al., 1997). According to the WHO definition (Hedinger et al., 1988), follicular carcinoma is 
defined as a malignant encapsulated epithelial tumors showing evidence of follicular cell 
differentiation but without the diagnostic features of papillary carcinoma. There is a close 
morphological resemblance between follicular adenoma and follicular carcinoma, and invasion 
of the capsule and/or capsular vessels is the key feature distinguishing the two types of tumor 
(Hedinger et al., 1988; Franssila 1997; Schlumberger 1998). Follicular carcinoma is divided 
into two major forms, depending on the degree of invasion, minimally invasive or widely 
invasive (Hedinger et al., 1988). Their distinction according to this criterion has a prognostic 
impact, because the widely invasive type has a less favorable prognosis (Lang et al., 1986). 
Follicular carcinoma typically disseminates in the bloodstream, and a distant metastasis, 
especially in the bone, may be the initial clinical symptom. Multicentricity and lymph node 
metastases occur infrequently compared to papillary carcinoma (Schlumberger 1998). 
Anaplastic thyroid carcinoma is a fast growing and usually lethal tumor. It accounts for 
2 to 15% of all thyroid carcinomas (Nel et al., 1985; Schlumberger and Pacini 1999; Kitamura 
et al., 1999). It is generally a disease of old age; most patients are more than 60 years old at the 
time of diagnosis (Ain 1998) and only few are under the age of 40 years (Venkatesh et al., 
1990). According to the WHO definition (Hedinger et al., 1988), the anaplastic carcinoma is too 
poorly differentiated to be placed in any of the other groups of thyroid carcinoma. Compared to 
the differentiated carcinomas, the clinical behavior of anaplastic carcinomas is very aggressive. 
Mean survival time is less than one year from diagnosis and median survival is about 2 months, 
regardless of the mode of treatment (Carcangiu et al., 1985; Nel et al. 1985; Kitamura et al. 
1999).     
Medullary carcinoma, derived from the parafollicular C-cells of the thyroid, is a rare 
disease, and  accounts for only 5% to 10% of all thyroid carcinomas (Williams 1966; 
Schlumberger and Pacini 1999; Wells et al., 2000). According to the WHO classification it is 
defined as a malignant tumor showing evidence of C cell differentiation (Hedinger et al., 1988). 
It can arise at any age and occurs as frequently in men as in women, differing in this respect 
from other thyroid tumors, which are more common in women (Franssila 1997). Sporadic or 
nonfamilial medullary carcinoma accounts for 60% to 70% of cases, with three distinct familial 
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syndromes (familial medullary thyroid carcinoma, multiple endocrine neoplasia (MEN) 
syndrome type IIA and type IIB) accounting for the remainder (Brunt and Wells 1987).  
Goiter is a non-neoplastic compensatory enlargement of the thyroid gland caused by 
thyroid hormone deficiency. It is the most common thyroid lesion. In diffuse goiter the gland is 
diffusely enlarged, and in nodular goiter nodules develop in the thyroid. It is also believed that 
nodular goiter may develop from diffuse goiter (Franssila 1997). Goiter is clearly more common 
in women than in men. 
 
5.2.  Parathyroid lesions 
 
Primary hyperparathyroidism (HPT) is a common endocrine disorder characterized by 
hypersecretion of parathyroid hormone (PTH) and the resultant hypercalcemia (Grimelius and 
Johansson 1997). Primary HPT is usually due to parathyroid gland hyperplasia or adenoma, or 
very rarely, to parathyroid carcinoma. It has been estimated that approximately 80 to 90% of 
patients with HPT harbor an adenoma, 10-20% have hyperplasia, and about 1% have 
parathyroid carcinoma (Akerstrom and Grimelius 1994; Grimelius and Johansson 1997). The 
differentiation between primary hyperplasia and adenoma may be difficult both clinically and 
histologically. One feature that differentiates primary parathyroid hyperplasia from parathyroid 
adenomas is the lack of a well-defined capsule, in the former, that separates the histologically 
altered tissue from a rim of normal parathyroid tissue. Parathyroid adenoma has been thought to 
be a true neoplasm, involving usually only one gland, whereas parathyroid hyperplasia is 
regarded as a non-neoplastic condition causing enlargement of all four parathyroid glands 
(Matsuhita 1997; Berger et al., 1999). However, these two entities cannot always be 
differentiated, and at least some adenomas might have their origin in antecedent parathyroid 
hyperplasia, and develop from the latter via a series of somatic mutations. Clonal analyses have 
suggested that in renal HPT parathyroid glands initially grow diffusely and polyclonally, after 
which the foci of nodular hyperplasia are transformed to monoclonal neoplasia (Tominaga 
1999a). Monoclonality has also been found in a minority of cases of primary parathyroid 
hyperplasia using X-chromosome inactivation analysis (Arnold et al., 1995). 
  
In secondary HPT, PTH secretion is increased as a physiological response to hypocalcemic 
conditions, for example in end stage renal disease or vitamin D-deficiency. Secondary HPT is 
usually associated with multiglandular parathyroid hyperplasia. Long-standing secondary HPT 
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may lead to autonomous PTH secretion, a state where the parathyroid glands have ceased to 
respond appropriately to physiological regulation. This is referred to as tertiary 
hyperparathyroidism (Mallya and Arnold 2000). 
 
5.3.  Risk factors for thyroid neoplasia and parathyroid proliferative lesions 
 
The risk factors for thyroid neoplasms have not been clearly identified. Prior radiation exposure 
is the only clearly demonstrated etiological factor, but it is probably responsible for only a small 
fraction of thyroid neoplasms. Radiation is a more effective thyroid carcinogen in children than 
adults (Ron et al., 1995; Busnardo and De Vido 2000). The relationship between radiation 
exposure and the occurrence of thyroid tumors became obvious after atomic bomb explosions 
during the Second World War and after the Chernobyl nuclear reactor accident in 1986. The 
Japanese survivors of the atomic bombs have experienced a 30-fold increase in thyroid cancer 
(Socolow et al., 1963). After the Chernobyl accident, an increased incidence of thyroid cancers, 
especially papillary carcinoma, was reported in children under 15 years of age, living in the 
Belarus and Ukraine close to the accident area (Furmanchuk et al., 1992). This increase in 
thyroid cancer was already apparent four years after the accident, and the incidence was 
reported to be 60-fold greater than it had been before the accident (Nikiforov et al., 1994). The 
incidence of benign thyroid tumors also increased considerably.  
In addition to radiation exposure, it has been suggested that there are other potential 
factors that may predispose to thyroid neoplasms. These include diet (particularly a diet rich in 
iodine and seafood), familial history, underlying thyroid disease, the effects of steroid hormones 
and occupational exposures to carcinogens (Langsteger et al., 1993; Franceschi et al., 1993). On 
the other hand, several studies have reported a higher prevalence of thyroid nodules and goiter 
in areas with an iodine deficiency than in areas with an adequate iodine intake (Belfiore et al., 
1992; Franceschi  et al., 1993; Galanti et al., 1995). In areas of low iodine intake and endemic 
goiter, follicular and anaplastic carcinomas are relatively more common than papillary 
carcinomas  compared to areas with a high iodine intake (Belfiore et al., 1992; Franceschi et al., 
1993). 
The incidence of thyroid neoplasia is also increased in certain familial syndromes, 
including familial adenomatous polyposis coli (Perrier et al., 1998), Cowden’s disease (the 
multiple hamartoma syndrome) and MEN type 1 (Busnardo and De Vido 2000).  It is not clear 
if familial syndromes or genetic diseases are associated with the development of differentiated 
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thyroid carcinoma. However, one study has suggested a propensity towards multifocal 
differentiated thyroid carcinoma in a small number of families (Grossman et al., 1995), and 
about 3% of cases of papillary carcinoma are reported to be familial (Malchoff et al., 1999). 
Medullary carcinoma differs from other thyroid carcinomas, in that about 30% of them have a 
genetic background (Brunt and Wells 1987). 
There are no known etiological factors that lead to the development of the sporadic form 
of hyperplasia or adenoma in primary HPT. However, there are a few studies suggesting that 
parathyroid adenoma occurs more frequently after irradiation of the neck or the thyroid, both in 
man and in rats (Rosen et al., 1975; Triggs and Williams 1977). Primary hyperplasia may also 
be a part of familial forms of HPT such as MEN types 1 or 2A. HPT can also be associated with 
other inherited syndromes, such as the hereditary HPT-jaw tumor syndrome, familial isolated 
HPT, and familial hypocalcuric hypercalcemia.  
Secondary HPT results from the compensatory over activity of the parathyroid glands in 
response to chronic hypocalcemia, usually caused by renal dysfunction. Less commonly it may 
be caused by calcium malabsorption, osteomalacia or deficient vitamin D metabolism. 
Sometimes, secondary HPT continues in spite of improvement in renal function, which is 
thought to represent tertiary hyperplasia.  
 
5.4.   Cytogenetic and molecular genetic changes 
5.4.1. The role of cytogenetic and molecular genetic changes in oncogene activation and 
tumor suppressor gene inactivation 
 
The development of cancer is a multistep process, where genetic alterations gradually lead to 
the transformation of a normal cell into a malignant one. Three groups of genes are targeted by 
mutations in cancer, oncogenes, tumor suppressor genes and DNA repair genes (Vogelstein and 
Kinzler 1998). Activation of oncogenes results in uncontrolled cell proliferation. There are 
several mechanisms by which oncogenes are activated, such as mutation, chromosomal 
translocation and gene amplification. These alterations can be studied using methods such as 
mutation analysis (mutations), conventional cytogenetic analysis (translocations, 
amplifications), and comparative genomic hybridization (amplifications). Tumor suppressor 
genes are negative regulators of cell growth (Vogelstein and Kinzler 1998), which through 
inactivation lead to uncontrolled cell growth. There are a few mechanisms, e.g. point mutations 
and deletions by which tumor suppressor genes can be inactivated. Mutation analysis is a 
method for studying mutations in known tumor suppressor genes. The losses of genetic material 
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may pinpoint the location of tumor suppressor genes. Methods such as conventional cytogenetic 
analysis, comparative genomic hybridization, loss of heterozygosity analysis and fluorescence 
in situ hybridization can be used to study losses of DNA sequences.  
 
5.4.2.  Chromosomal aberrations and DNA copy number changes 
 
It has been suggested that thyroid lesions do not represent independent entities, but different 
steps of a histological development from normal follicular cell to adenoma, from adenoma to 
follicular carcinoma, and from differentiated carcinoma to anaplastic carcinoma (Williams 
1995) (Fig. 2.). However, there is only limited evidence for this so-called adenoma-carcinoma 
sequence of development in the thyroid follicular cell. The findings in loss of heterozygosity 
studies suggest that papillary thyroid carcinoma and follicular carcinoma develop along distinct 
pathogenic pathways (Learoyd et al. 2000). Some reports suggest that papillary carcinoma 
originates de novo from the normal follicular epithelium, whereas the progression of follicular 
carcinoma may follow a sequential normal – adenoma – carcinoma multistep pathway 
(Wynford-Thomas and Williams 1989; Roque et al., 1999). Some adenomas and goiters have 
similar cytogenetic abnormalities, so it is possible that such a pathway could include even 
goiters (Belge et al., 1998). Polysomies of chromosomes 7 and 12 and structural aberrations 
involving 19q13 are examples of changes that have been detected in a subgroup of follicular 
thyroid adenomas and in some goiters (Bartnizke et al., 1989; Bondenson et al., 1989; Teyssier 
et al., 1990; Gama et al., 1991; Dal Cin et al., 1992; Herrmann and Lalley 1992; Antonini et al., 
1993; Roque et al., 1993a; Roque et al., 1993b; Criado et al., 1995; Belge et al., 1998; Roque et 
al., 1999; Barril et al., 2000). Interestingly, trisomies of chromosomes 7 and 12 have also been 
detected in papillary carcinomas, where they have been associated with a poor clinical outcome 
(Teyssier et al., 1990; Herrmann and Lalley 1992; Taruscio et al., 1994; Roque et al., 1995), and  
in follicular carcinoma (Teyssier et al., 1990; Roque et al., 1998a). However, some recent 
studies support the hypothesis that follicular thyroid adenomas and carcinomas develop along 
two distinct pathways (Zedenius et al., 1996; Dahia et al., 1997; Marsh et al., 1997; Frisk et al., 
1999; Yeh et al., 1999). A meta-analysis of LOH studies in thyroid cancer has confirmed high 
rates of LOH in follicular carcinomas (Table 1), and low rates in papillary thyroid carcinomas 
and follicular adenomas (Ward et al., 1998). These results suggests fundamental differences in 
the pathogenesis of these two types of carcinoma. The hypothesis is further supported by a 
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recent finding of frequent LOH at 7q in follicular and anaplastic carcinomas, but not in papillary 
carcinoma (Trovato et al., 1999).  
 
Figure 2. Proposed genetic model of thyroid tumorigenesis. Modified from Learoyd et al., 2000. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
     
         
 
 
 
 
 
 
 
 
 
 
 
 
 
The cytogenetics of follicular thyroid adenoma have been extensively studied, and clonal 
chromosomal abnormalities have been detected in 30-45% of them (Bondeson et al., 1989; 
Teyssier et al., 1990; van den Berg et al., 1990; Sozzi et al., 1992b; Antonini et al., 1993; Roque 
et al., 1993a; Belge et al., 1994; Criado et al., 1995; Belge et al., 1998). The most frequent 
anomalies in benign thyroid adenomas are trisomies of chromosomes 4, 5, 7, 9, 12, 16, 17, 18, 
20 and 22 (van den Berg et al., 1990; Antonini et al., 1993; Roque et al., 1993a; Heim et al., 
1995; Belge et al., 1998; Mazzucchelli et al., 2000), deletions in or of chromosome 2 (Belge et 
al., 1996; Tallini et al., 1999), translocation t(2;3) (q12-q13;p24-p25) (Sozzi et al., 1992b), 
translocation t(5;19) (q13;q13) (Belge et al., 1991), deletions of the long arm of chromosome 13 
(Belge et al., 1991, 1998), 19q13 abnormalities (Belge et al., 1992; Dal Cin et al., 1992), and 
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monosomy 22 (Belge et al., 1998). Furthermore, deletions of 10q and 11q13 have been revealed 
in loss of heterozygosity analyses (Zedenius et al., 1995, 1996; Yeh et al., 1999).  
Information about chromosomal abnormalities in follicular thyroid carcinoma is limited, 
only about 70 of these cancers with cytogenetic alterations have been described (Bondeson et 
al., 1989; Herrmann MA et al., 1991; Jenkins et al., 1990; Roque et al., 1993c; Teyssier et al., 
1990; van den Berg et al., 1991; Roque et al., 1999; Mazzucchelli et al., 2000). Loss of the short 
arm of chromosome 3 is one of the alterations described. The segment 3p25-pter appears to 
constitute a minimal common deleted region, and it has been speculated that this may be a 
critical event in the malignant transformation of a subset of follicular thyroid neoplasms 
(Jenkins et al., 1990; Teyssier et al., 1990; Herrman MA et al., 1991; van den Berg et al., 1991; 
Roque et al., 1993c; Grebe et al., 1997; Lui et al., 2000). However, other studies on allelotypes 
of follicular thyroid carcinomas detected the loss of the 3p allele in only 5 to 30% of samples 
(Zedenius et al., 1996; Tung et al., 1997; Roque et al., 1998a). Deletions in other chromosomal 
regions, such as 2p, 2q, 10q, 11p, 11q, 17p, and 22q have also been frequently observed in 
follicular carcinomas (Zedenius et al., 1995, 1996; Tung et al., 1997; Grebe et al., 1997; 
Kitamura et al., 2001). Grebe and coworkers (1997) have suggested that 3p and 10q LOH may 
represent an early event and 17p LOH a late event in follicular carcinoma development. One 
report suggests that t(7;8)(p15;q24) may be associated with aggressive growth of follicular 
thyroid carcinomas (Roque et al., 1998a).  
Papillary thyroid carcinoma is the most extensively studied type of thyroid carcinoma 
(Bondeson et al., 1989; Jenkins et al., 1990; Teyssier et al., 1990; Herrmann MA et al., 1991; 
Herrmann ME et al., 1991 Antonini et al., 1992; Sozzi et al., 1992a; Roque et al., 1995; 
Lehmann et al., 1997; Roque et al., 2001). These studies reported the presence of nonrandom 
chromosomal changes, with chromosomes 1, 3, 5, 7, 10, 17 and 20 being the most frequently 
affected by numerical and structural aberrations. The karyotypic abnormalities are usually 
simple, and the most frequent abnormality in papillary carcinomas is the structural 
rearrangements of chromosome 10 at band 10q11.2 (Jenkins et al., 1990; Grieco et al., 1990; 
Herrmann MA et al., 1991; Herrmann ME et al., 1991; Sozzi et al., 1992a; Roque et al., 2001). 
Several authors have found papillary carcinoma to show a low rate of LOH (Herrmann MA et 
al., 1991; Califano et al., 1996; Grebe et al., 1997; Ward et al., 1998).  
Little is known about the genetic mechanisms that result in the development of 
anaplastic thyroid carcinoma. Conventional cytogenetic data are limited to only eight anaplastic 
carcinomas (Mark et al., 1987; Jenkins et al., 1990; Roque et al., 1998b). Most of these tumors 
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had complex karyotypes that included signs of gene amplification in the form of double minute 
chromosomes (Mark et al., 1987). However, anaplastic carcinoma appears to have no 
characteristic cytogenetic pattern. LOH studies on anaplastic carcinomas are also rare, and only 
29 cases have so far been studied (Zedenius et al., 1996; Ward et al., 1998; Kitamura et al., 
2000). Frequent allelic losses have been identified in 1q, 9p, 10q, 11p, 17p, 17q, 19p and 22q 
(Zedenius et al., 1996; Kitamura et al., 2000).  
Cytogenetic studies on medullary thyroid carcinoma are also limited. A hypodiploid 
chromosomal number in the range of 34 to 44 has been reported in primary medullary 
carcinoma tissue (Wurster-Hill et al., 1990; Tanaka et al., 1987), and the tumor is associated 
with a constitutional minute deletion in the short arm of chromosome 20 [del(20)(p12.2)] (Babu 
et al., 1987).  
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Table 1. Summary of the cases of LOH in different thyroid neoplasms reported in the literature. 
 
Thyroid neoplasms Chromosome arm (% LOH) 
  
Follicular adenoma  
Herrman MA et al., 1991 (n=3) - 
Grebe et al. , 1997 (n=7) 1p (14), 3p (14), 10q (28), 11p (14) 
Marsch et al., 1997 (n=19) 10q (26) 
Zedenius et al., 1996 (n=19) 1p (16), 3p (16), 10p (32), 10q (42), 13q (21) 
Ward et al., 1998 (n=24) 3p (20), 10q (20) 
Nord et al., 1999 (n=39) 11q (18)  
Yeh et al., 1999 (n=44) 10q (43) 
  
Follicular carcinoma  
Herrmann MA et al., 1991 (n=6) 3p (100) 
Zedenius et al., 1996   Widely (n=4) 1p (11), 3p (11), 10q (22), 13q (11) 
                                Minimally (n=5) - 
Grebe et al., 1997 (n=14) 3p (86), 3q (36), 10p (22), 10q (57), 11p (22), 13q (43), 
17p (72) 
Marsch et al., 1997 (n=10) - 
Tung et al., 1997 (n=28) 1p (35), 1q (27), 2p (50), 2q (50), 3p (30), 3q (32), 4p 
(35), 4q (24), 6p (26), 6q (23), 8p (23), 8q (33), 9p (33), 
9q (44), 11p (33), 11q (22), 14q (27), 15q (32),  
16p (23),16q (24), 21q (25), 22q (30) 
Ward et al., 1998 (n=10) 2p (33), 3p (30), 11q (33) 
Yeh et al., 1999 (n=17) 10q (24) 
Kitamura et al., 2001 (n=66) 7q (28), 11p (28), 22q (41) 
  
Papillary carcinoma  
Herrmann MA et al., 1991 (n=12) - 
Califano et al., 1996 (n=30) 4q (21), 5p (17), 7q (17), 11p (10) 
Grebe et al., 1997 (n=14) 3p (29), 10q (14), 17p (22) 
Ward et al., 1998 (n=30) 3p (12), 10q (15) 
Kitamura et al., 2000   
(n=45 survived cases) 22q (19) 
(n=24 deceased cases) 1q (37), 4p (21), 7q (20), 9p(36), 9q (31), 16q (29),  
22q (33)  
  
Anaplastic carcinoma  
Zedenius et al., 1996 (n=6) 3p (22), 10p (11), 10q (22), 13q (22) 
Ward et al., 1998 (n=1) - 
Kitamura et al., 2000 (n=21) 1q (41), 9p (58), 11p (33), 11q (33), 17p (44), 17q (43), 
19p (36), 22q (38) 
 
 
 
From the point of view of the genesis of parathyroid tumors, several interesting chromosomal 
locations have recently been pointed out in cytogenetic studies. These include 11q13 (the 
MEN1 locus, Chandrasekharappa et al., 1997; Heppner et al., 1997), 1q21-32 (linked to 
hyperparathyroidism-jaw tumor syndrome) and 1p. Loss of heterozygosity in these regions has 
been observed in 30% of sporadic and most familial parathyroid tumors (Friedman et al., 1989, 
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1992; Thakker et al., 1989; Cryns et al., 1995; Tahara et al., 1996; Farnebo et al., 1997; Teh et 
al., 1998a; Dwight et al., 2000). Somatic inactivation of the two MEN1 alleles has been found in 
12 to 21% of sporadic parathyroid tumors (Heppner et al., 1997; Carling et al., 1998; Farnebo et 
al., 1998). Presence of another tumor suppressor gene, distinct from MEN1, may be present in 
chromosome band 11q13 (Chakrabarti et al., 1998). In addition to these changes, LOH has been 
found at several genomic loci. Regions are frequently lost in chromosomal arms 3q, 6q, 11p, 
13q and 15q (Cryns et al., 1995; Thompson et al., 1995; Dotzenrath et al., 1996; Iwasaki et al., 
1996; Pearce et al., 1996; Tahara et al., 1996; Palanisamy et al., 1998). DNA alterations 
involving the parathyroid hormone gene (PTH) locus at 11p15 may also have some role in the 
tumorigenesis or clonal evolution of some parathyroid adenomas (Arnold et al., 1988). Allelic 
loss at 13q, including the tumor suppressor gene RB1, has been detected in 16% to 30% of 
parathyroid adenomas, and even more frequently in parathyroid carcinomas (Cryns et al., 1995; 
Dotzenrath et al., 1996; Pearce et al., 1996; Tahara et al., 1996; Palanisamy et al., 1998). 
 
5.4.3.  Molecular genetic changes 
 
In recent years progress in molecular biology has generated new information about the genetic 
abnormalities involved in the pathogenesis of thyroid tumors, and a number of thyroid cancer-
associated genes have been identified. Rearrangements (RET/PTC, NTRK) or gene 
amplifications (CMET) involving the tyrosine kinase domain are common in papillary thyroid 
carcinoma (Fusco et al., 1987; Bongarzone et al., 1989; Di Renzo et al., 1992; Santoro et al., 
1992; Pierotti et al., 1996). RET/PTCs are generated by the fusion of the tyrosine kinase (TK) 
domain of RET to the 5’-terminal sequence of another gene such as the gene H4 in RET/PTC-1 
(Pierotti et al., 1992) or ELE1 in RET/PTC-3, resulting in constitutive expression of the RET 
TK (Santoro et al., 1994; Jhiang et al., 1994). This may occur through chromosomal inversion 
(as in RET/PTC-1 and –3) or by translocation, such as in RET/PTC-2, where the regulatory 
subunit R1α of protein kinase A is fused to the TK domain of RET (Bongarzone et al., 1993; 
Sozzi et al., 1994). Although these genes have different functions, they share the same 
ubiquitous pattern of expression. Some novel types of rearrangement, namely RET/PTC5, 
RET/PTC6, RET/PTC7, RET/PTC8, RET/ELKS and RET/PCM-1 (Klugbauer et al., 1998; 
Klugbauer and Rabes, 1999; Nakata et al., 1999; Corvi et al., 2000; Klugbauer et al., 2000) have 
recently been identified. RET rearrangements, in papillary carcinomas unassociated with 
irradiation, occur with variable frequency, from approximately 3% to 33% (Santoro et al., 1992; 
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Zou et al., 1994; Bongarzone et al., 1996). Youth and radiation exposure are each independent 
risk factors for the presence of RET/PTCs (Nikiforov et al, 1997). Recent studies have 
suggested that RET rearrangements may play a role in early tumorigenesis, and they do not seem 
to be associated with tumor progression (Viglietto et al., 1995; Sugg et al., 1998; Tallini et al., 
1998).  
Mutations in RET have also been found in sporadic medullary thyroid carcinomas 
(Donis-Keller et al., 1993; Eng et al., 1995; Bolino et al., 1995; Marsh et al., 1996; Smith et al., 
1997; Blaugrund et al., 1994; Learoyd et al., 2000), in which the most frequent mutation is the 
ATG to ACG substitution in codon 918 found in MEN 2B. This mutation has been associated 
with a poor prognosis in some (Zedenius et al., 1995) but not in all studies (Marsh et al., 1996; 
Eng et al., 1998). Other somatic mutations in RET have been observed in a small number of 
sporadic medullary thyroid carcinomas, such as the mutation of codon 883 in exon 15 (Marsh et 
al., 1996). 
The neutrotrophic tyrosine kinase receptor type 1 gene (NTRK1), which encodes a cell 
surface receptor for nerve growth factor, has been found to be activated in some papillary 
carcinomas, either through intrachromosomal gene rearrangements or through unequal 
crossovers between the two copies of chromosome 1 (Greco et al., 1992; Pierotti et al., 1996).   
Mutations in all three members of the RAS oncogene family (HRAS, KRAS and NRAS), 
have been found in thyroid tumors  (Lemoine et al., 1989; Suarez et al., 1990, Suarez 1998). 
There is no difference in the frequency of RAS mutations between benign or malignant thyroid 
neoplasms (Karga et al., 1991). However, activating point mutations of RAS have been found 
frequently in follicular thyroid adenomas and carcinomas but not in papillary carcinomas 
(Lemoine et al., 1989; Suarez et al., 1990; Karga et al., 1991). It has been suggested that RAS 
mutations may represent as an early event in thyroid tumorigenesis, at a stage prior to the loss of 
differentiation (Namba et al., 1990; Gire and Wynford-Thomas 2000).  
The TSH receptor is one of a family of seven transmembrane domains coupled to G-
proteins. Somatic mutations of the TSH receptor gene (TSHR)(located at 14q31) have been 
found to cause constitutive activation of downstream events in a subset of hyperfunctioning 
adenomas (Parma et al., 1993; Polak 1999; Tonacchera et al., 1999). Activating TSHR 
mutations have been detected in up to 80% of these adenomas, and up to 25% also have 
mutations in the Gs (alpha) gene (GSP), suggesting that these genetic anomalies may play a role 
in the pathogenesis of hyperfunctioning adenoma (Lyons et al., 1990; Suarez et al., 1991; 
Duprez et al., 1998; Tonacchera et al., 1999). However, there are still discrepancies in the 
    
 
26 
frequency of TSHR mutations in hyperfunctioning thyroid nodules (Duprez et al., 1998). It has 
also been suggested that oncogenes other than TSHR and Gs (alpha) may be involved in the 
pathogenesis of nonfunctioning follicular adenomas (Tonacchera et al., 1999). The role of 
TSHR does not seem to have any significant role in the genesis of other thyroid tumors (Matsuo 
et al., 1993). 
So far, TP53 gene and beta-catenin mutations are the only genetic alterations that have 
been implicated in the pathogenesis of anaplastic carcinomas (Ito et al., 1992; Fagin et al., 1993; 
Garcia-Rostan et al., 1999). Point mutations in TP53 (a tumor suppressor gene located at 
17p13.1) appear to be frequent in anaplastic carcinoma, but not in the differentiated carcinomas, 
suggesting that TP53 mutations might be important in the putative progression of differentiated 
carcinoma to anaplastic carcinoma (Ito et al., 1992; Fagin et al., 1993; Ain 1998). P53, the 
tumor protein encoded by TP53 offers protection against cancer development in two ways: 1) it 
arrests the cell cycle allowing damaged DNA to undergo repair; and 2) it allows damaged cells 
to undergo apoptosis instead of dividing thereby avoiding the passage of damaged DNA to the 
next generation of cells (Greenblatt et al., 1994). Disruption of these protective functions may 
be relevant in the progression of thyroid neoplasms to an aggressive, undifferentiated 
phenotype.  
The roles of other tumor suppressor genes, such as PTEN (phosphatase and tensin gene 
homolog) at 10q23.3 and APC (adenomatosis polyposis coli gene), have also been studied in the 
context of the  molecular pathogenesis of thyroid neoplasms. Some reports suggests that the 
PTEN gene has a role in the genesis of follicular tumors (Dahia et al., 1997; Halachmi et al., 
1998; Yeh et al., 1999; Gimm et al., 2000), where it appears to be involved in the development 
of follicular adenomas but not of carcinomas. PTEN is often deleted, especially in atypical 
adenomas (Marsch et al., 1997).   
In about 5% of parathyroid adenomas, a pericentromeric inversion of chromosome 11 
has been detected, which results in a gene rearrangement involving the PTH gene at 11p15 and 
the cyclin D1 gene at 11q13 (Arnold et al., 1989; Motokura et al., 1991; Arnold 1995). There 
are no accurate estimates of the percentage of parathyroid adenomas that harbor such cyclin D1-
activating rearrangements. However, in immunohistochemistry studies, 20 to 40% of 
parathyroid adenomas overexpress cyclin D1 (Hsi et al., 1996; Tominaga et al., 1999b; Vasef et 
al., 1999; Mallya and Arnold 2000). Additional genetic abnormalities, such as gene 
amplification, rearrangement with other parathyroid specific promoters or transcriptional 
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activation, are probably involved in cyclin D1 overexpression. In one immunohistochemistry 
study cyclin D1 expression was found in 61% of parathyroid hyperplasias (Vasef et al., 1999).  
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6.  AIMS OF THE STUDY 
 
 
 
• To investigate DNA sequence copy number changes using comparative genomic 
hybridization in  thyroid and parathyroid neoplasms and parathyroid hyperplasia. 
 
• To investigate the role of cyclin D1 overexpression in parathyroid neoplasms and     
  hyperplasia. 
 
 • To study the role of deletion at 11q23 in parathyroid lesions using the CGH results. 
 
•  To study, specifically, the role of PPP2R1B as a putative suppressor gene mapping to 
11q23 
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7.  MATERIALS AND METHODS 
7.1.  Patients and tumor specimens  
 
In study I, 29 cases of follicular adenoma and 13 cases of follicular carcinoma of the thyroid 
were analyzed. All the samples were from fresh frozen tumors, obtained from the frozen tissue 
bank at the Department of Pathology, Helsinki University Central Hospital. Sections were cut 
from frozen tissue, stained with toluidine blue, and examined to verify that the sample contained 
mainly tumor tissue. The samples comprised at least 70% tumor cells. Twenty-four (83%) of the 
patients from whom the adenoma samples came, and 10 (77%) of those from whom the 
carcinoma samples came, were women. The median age at diagnosis of the patients with 
follicular adenoma was 46 years (range, 25 to 87) and that of patients with follicular carcinoma 
71 years (range, 34 to 85). All original histological diagnoses were re-examined without 
knowledge of the CGH results. The tumors were classified according to the World Health 
Organization (WHO) classification (Hedinger et al, 1989). 
Sixty-nine thyroid carcinoma patients were included in Study II. Of these carcinomas, 26 
were of the papillary histological type, 20 were follicular, 10 were medullary and 13 were 
anaplastic. The diagnoses were made in the Department of Pathology at Helsinki University 
Central Hospital, between 1981 and 1997. The patients were chosen for analysis based on the 
availability of fresh frozen tumor tissue (n=53), or at random whenever paraffin-embedded 
tissue was used (n=16). The histological sections were re-examined, and one pathologist (K. 
Franssila) reclassified the tumors according to the WHO classification (Hedinger et al., 1989). 
The clinical stage was determined according to the International Union Against Cancer (UICC) 
TNM (tumor node metastases) classification (UICC 1997).  
In Study III 47 patients with parathyroid lesions were investigated (Table 2). The 
histological samples were obtained from patients who underwent parathyroid surgery at the 
Department of Surgery, Helsinki University Central Hospital. Eleven were men, and the median 
age was 61 years (range, from 29 to 90). Sixteen patients had primary parathyroid hyperplasia, 
four patients had hyperplasia with MEN1 syndrome, three had secondary hyperplasia related to 
chronic renal failure, and three had uremic parathyroid hyperplasia that had become refractory 
to medical treatment (tertiary hyperplasia). The patients with secondary hyperplasia due to renal 
disease had been subjected to parathyroid surgery so that the disease could be more easily 
controlled using medical therapy (n=2), or the parathyroid was removed in conjunction with 
thyroid surgery (n=1). Sixteen further patients had been diagnosed with parathyroid adenoma. In 
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addition, we studied five cases where the excised sample contained only histopathologically 
normal parathyroid tissue. One parathyroid gland was examined using CGH in each of the 47 
patients except for five of the patients with hyperplasia, from whom two to four glands were 
examined. A total of 34 hyperplastic parathyroid glands from 26 patients were investigated, and 
the total number of parathyroid glands studied using CGH in the entire series was 55.  
One pathologists (K. Franssila) re-examined all the original histological sections. The 
differential diagnosis between adenoma and hyperplasia was based on the following criteria: 1) 
parathyroid adenoma was diagnosed when there was an encapsulated parathyroid lesion with no 
fat cells. In all cases there was apparently normal parathyroid tissue with fat cells outside the 
lesion capsule area; 2) parathyroid hyperplasia was diagnosed when at least two enlarged 
parathyroid glands were present with no normal parathyroid tissue identified outside the capsule 
of the lesion. In the lesion, there was either diffuse proliferation of enlarged parathyroid chief 
cells with no fat cells, or nodular proliferation of chief cells sometimes with some fat cells 
between the nodules. Two MEN1-related hyperplasias were classified as nodular and two as 
diffuse. All the hyperplastic lesions involved chief cells except for one case, in which the water-
clear cells were hyperplastic. 
Eighteen patients with parathyroid lesions were examined in Study IV, all of whom had 
also participated in Study III. Six of them had parathyroid hyperplasia; three cases of primary 
hyperplasia, one case of MEN1 syndrome with hyperplasia and two cases of tertiary parathyroid 
hyperplasia. Twelve patients had parathyroid adenoma. One parathyroid gland was examined 
from each of the 18 patients except for one patient with primary hyperplasia, from whom two 
glands were examined. A total of nineteen parathyroid lesions were therefore studied. Eight of 
these lesions (3 hyperplasias and 5 adenomas) showed deletion of 11q23 in a CGH analysis 
described in detail elsewhere (Hemmer et al., 1999) and in 7.2.1. below. 
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Table 2. Summary of Material and Methods. 
 
Study Organ Number of cases 
studied 
Methods used 
Study I Thyroid 
  Follicular adenoma 
  Follicular carcinoma 
 
29 
13 
CGH 
Study II Thyroid 
  Papillary carcinoma 
  Follicular carcinoma 
  Medullary carcinoma 
  Anaplastic carcinoma 
 
26 
20 
10 
13 
CGH,  
FISH (#22)  
DOP-PCR 
Study III Parathyroid 
  Primary hyperplasia 
  Adenoma 
  Secondary hyperplasia 
  Tertiary hyperplasia 
  MEN1-related hyperplasia  
  Normal parathyroid tissue 
 
 
16 
16 
  3 
  3 
  4  
  5 
CGH 
FISH (YAC probes for 11q23, 
11p13, and MEN1 probe) 
DOP-PCR  
Immunohistochemistry (cyclin 
D1) 
Study IV Parathyroid 
  Primary hyperplasia 
  Tertiary hyperplasia 
  MEN1-related hyperplasia 
  Adenoma 
 
 
  3 
  2 
  1 
12 
SSCP analysis 
Sequence analysis 
 
 
7.2.  Methods 
7.2.1. Comparative genomic hybridization (Studies I, II and III) 
 
Comparative genomic hybridization (CGH) (Table 2) was performed on samples from thyroid 
tumors and from parathyroid lesions (Studies I, II and III) according to the protocol described by 
Kallioniemi and coworkers (1994) and slightly modified by us as described earlier elsewhere 
(El-Rifai et al., 1997).  
Histological sections from either frozen or paraffin-embedded tissue were cut, stained 
with toluidine blue or haematoxylin, respectively, and examined for the presence of 
representative tumor tissue. In all cases at least 70% of the cells analyzed were cancer cells. 
From each tumor specimen 20 to 30 5-µm sections were also cut, from which genomic DNA 
was extracted as described earlier (Sambrook et al., 1989; Isola et al., 1994). DNA from 
peripheral blood samples of healthy men and women, which was used as normal reference DNA 
in the hybridization and the negative control experiments, was extracted according to standard 
methods. Metaphase slides were prepared from phytohemagglutinin-stimulated peripheral blood 
lymphocytes from healthy individuals, according to standard procedures (Studies I, II and III).  
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Tumor and parathyroid hyperplasia DNA (test DNA) was labeled with fluorescein 
isothiocyanate (FITC)-dUTP and FITC-dCTP (1:1; Dupont, Boston, MA, USA), and the normal 
reference DNA was labeled with Texas-red-dUTP and Texas-red-dCTP (1:1; Dupont, Boston, 
MA, USA) in a standard nick-translation reaction. The nick-translation reaction was optimized 
to produce labeled DNA fragments of 600 to 2000 base pairs in length. The length of the DNA 
fragments was evaluated by electrophoresis in a 1.4% non-denaturing agarose gel. 
  Equal amounts (1 µg) of the labeled test and reference probes were used for 
hybridization together with 10 µg of unlabeled human Cot-1 DNA to block the binding of 
repetitive sequences in 10 µl of the hybridization buffer [50% formamide, 10% dextran sulfate, 
2X SSC (1X SSC is 0.15 mol/L sodium chloride/0.015 mol/L sodium citrate, pH 7)]. The DNA 
was then denatured for 5 minutes at 75 °C before applying it to normal metaphase spreads. 
Before hybridization, the metaphase preparations were dehydrated in a series of 70%, 80% and 
100% ethanol and denatured at 65 °C for 2 min in a formamide solution (70% formamide/2 x 
SSC). The slides were then dehydrated on ice as described above, and then treated with 
proteinase-K at 37 °C for 7.5 min (0.2 µg/ml in 20 mM Tris-HCl, 2 mM CaCl2, pH 7), and 
once again dehydrated in a series of rising ethanol concentrations as described above. 
Hybridization was performed in a moist chamber at 37 °C for 48 hours. Posthybridization 
washes were as follows: 3 times in 50% formamide/2xSSC/pH 7, twice in 2xSSC, and once in 
0.1xSSC at 45 °C followed by 2xSSC and 0.1 M NaH2 PO4/0.1 M Na2HPO4/0.1% Nonidet 
P40/pH 8 and distilled water at room temperature for 10 min each.
 
The slides were 
subsequently counterstained with 4´, 6-diamidino-2-phenylindole (DAPI, Sigma, St. Louis, MO, 
USA) at a concentration of 0.1 µg/ml in an anti-fade solution (Vector Laboratories Inc., 
Burlingame, CA, USA).  
The results were analyzed using an Olympus fluorescence microscope and an ISIS 
digital image analysis system (Metasystem GmbH, Altlussheim, Germany) that included a high-
sensitivity integrated monochrome CCD camera and an automated CGH analysis software 
package. The three-color images, green (FITC) and red (Texas Red) for the test and reference 
hybridizations, respectively, and blue (DAPI) for the counterstain on the chromosomes, were 
scored from 8-10 metaphases per sample. Only metaphases of good quality, with strong uniform 
hybridization, were included in the analysis. Chromosomes not suitable for analysis were 
excluded (e.g. chromosomes that were heavily bent, overlapping, or those that had overlying 
artifacts). The intensity ratios of the green and red colors were calculated along each 
    
 
33 
chromosome and if no gains or losses were found, the ratio of the two fluorochromes was 1. 
Chromosomal regions were interpreted as over-represented (gained) when the red to green ratio 
exceeded 1.17, and underrepresented (lost) when the ratio was less than 0.85. Ninety-nine 
percent confidence limits with 1% error probability were used to confirm the interpretation. The 
cut-off values were taken from negative control experiments using differentially labeled male 
DNA versus female DNA. Chromosomal areas with an average ratio profile exceeding 1.5 were 
considered to be highly amplified. A positive control with known chromosomal aberrations and 
a negative control (peripheral blood DNA from a healthy donor) were included in each 
hybridization batch to verify the reliability of the method. Chromosomal regions in the 
centromeric areas of chromosomes 1, 9, 16 and Y, and the p-arms of acrocentric chromosomes 
were discarded from the analysis because of their large heterochromatic areas.  
To confirm the CGH results, additional hybridization experiments using the reverse-
labeling system (Larramendy et al., 1998), i.e. tumor DNA labeled with Texas Red and 
reference DNA with FITC, were performed on some specimens. 
 
7.2.2. Fluorescence in situ hybridization (Studies II and III) 
 
DNA probes 
To confirm deletion of chromosome 22, we used a LSI DiGeorge/VCFS probe mixture 
(purchased from Vysis Ahdiagnostics, Skarholmen, Sweden), which contains a 
SpectrumOrange TUPLE 1 probe located at 22q11.2 and a SpectrumGreen LSI ARSA 
(arylsulfatase A gene) probe that maps close to the telomeric end of 22q at 22q13.3. 
 
Yeast artificial chromosome (YAC) clones. YAC clone 755b11 (D11S1986, about 400 kb 
from PPP2R1B gene according to Ensembl Human Genome Server) obtained from the Centre 
d’Etude Polymorphisme d’Humain (CEPH, Paris, France) was used to detect deletion of the 
chromosome region 11q23.1 using fluorescence in situ hybridization (FISH). Four samples in 
which 11q deletions were detected using CGH and 14 samples with no 11q deletion were 
investigated. The YAC probe 953e4, which hybridizes to 11p13, was used as a control for 
hybridization efficiency and for evaluation of the chromosome copy number in these 
experiments. A MEN1 gene-specific cosmid clone c10B11, which maps to 11q13, was obtained 
from David Gisselsson (Department of Clinical Genetics, University Hospital, Lund, Sweden), 
and was used in nine cases to determine the MEN1 gene copy number (Guru et al., 1997).  
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Hybridization 
Nucleus Extraction and fluorescence in situ hybridization (FISH) 
FISH was performed to confirm the CGH results. The nuclei from paraffin-embedded tissue 
were extracted as described elsewhere (Heiden et al., 1991; Hyytinen et al., 1994) with slight 
modifications. Briefly, four 30 µm sections were deparaffinized and incubated in 1 ml of 
Carlsberg’s solution (0.1% Sigma protease XXIV, 0.1 M Tris, 0.07 M NaCl, pH 7.2) for 1 hour 
at +37 ºC and vortexed vigorously for 20 minutes. The nuclear suspension was filtered through 
a nylon mesh (pore size 55 µm), centrifuged, and diluted in 0.1 M Tris. The nuclear suspension 
was then spread on slides and checked microscopically.         
All probes were labeled with biotin-14-dATP (Gibco, Bethesda Research Laboratories, 
USA) by nick-translation, precipitated with herring sperm DNA (0.62 µg/µl) (Sigma) and 
human Cot-1 DNA (0.62 µg/µl, Gibco), and dissolved in a hybridization buffer containing 50% 
formamide, 20% dextran sulfate and 2 x SSC. To ensure penetration of the probe, the slides 
were treated in 1 M sodium thiocyanate at +70 ºC for 15 minutes, followed by treatment in 0.05 
N HCl at +37 ºC for 10 minutes, and by 5 mg/ml pepsin in 0.05 N HCl at +37 ºC for 20 
minutes. The slides were then dehydrated in a rising alcohol series (70%, 85% and 100%) and 
denatured in 70% formamide/2 x SSC, pH 7 at +75 ºC for 5 minutes, followed by dehydration 
in a cold alcohol series. The probes were denatured at 75 ºC for 5 minutes and applied onto the 
slides. Hybridizations were performed at 37 ºC for 2 days. Post-hybridization washes were 
performed at 45 ºC in 50% formamide, 3 times in 2 x SSC, pH 7.0 for 5 minutes each, once in  
2 x SSC, pH 7.0 for 5 minutes, twice in 0.1 x SSC, pH 7.0 for 5 minutes each, and finally in  
4 x SSC, 0.2% Tween (Sigma), pH 7.0 at room temperature for 5 minutes. For detection of 
signals, FITC conjugated avidin (Vector Laboratories Inc.) was used.  The signals were then 
further amplified with anti-avidin D/avidin-FITC (Vector Laboratories Inc.). Finally, slides 
were counterstained with DAPI (Sigma), and mounted with an anti-fade solution (Vector 
Laboratories Inc). From each preparation a minimum of 100 morphologically intact and non-
overlapping nuclei were scored using a Leitz fluorescence microscope (Laborlux D, Germany).   
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7.2.3.  Degenerate oligonucleotide-primed polymerase chain reactions (Studies II and III)    
 
In four samples, which did not contain enough DNA for CGH, we amplified genomic DNA by 
using the degenerate oligonucleotide-primed polymerase chain reaction (DOP-PCR). Five µl of 
the extracted DNA was used as a template for the DOP-PCR using a universal primer  
(5´-CCGACTCGAGNNNNNNATGTGG-3´, with N=A, C, G, or T) with some modifications 
(Kuukasjärvi et al., 1997; Tapper et al., 1998). We applied the Thermosequenase enzyme 
(Amersham, Cleveland, OH) diluted 1:10 (3 units/reaction) in a dilution buffer (10mM Tris-
HCl, pH 8.0, 1mM 2-mercaptoethanol, 0.5% Tween-20, 0.5% Nonidet P40) in a volume of 10 
µl (26mM Tris-HCl, pH 9.5, 6.5mM MgCl2, 0.2mM dNTPs, 1 µM universal primer) by using 6 
cycles of 94 ºC for 1 min, 30 ºC for 3 min and 65 ºC for 5 min, followed by a final extension at 
72 ºC for 10 min. This was followed by high stringency cycles consisting of an initial melting at 
95 ºC for 3 min and 30-35 cycles of 94 ºC for 1 min, 56 ºC for 1 min and 72 ºC for 2 min with a 
final extension at 72 ºC for 5 min, in a volume of 50 µl using the same reaction conditions as 
above except for 2 µM instead of 1µM of universal primer. 
The DOP-PCR product was labeled using a standard nick translation (El-Rifai et al., 
1997). The slides were counterstained with DAPI (Sigma) to identify the chromosomes.  
In each DOP-PCR experiment, a tube without DNA was included as a negative control. 
For a positive control, DNA from a tumor with a known DNA copy number was included, as in 
the CGH procedure. 
 
7.2.4.    Immunohistochemistry (Study III) 
 
Cyclin D1 immunostaining was performed on 3 µm deparaffined sections from 47 parathyroid 
samples. Deparaffination was carried out at room temperature using an Autostainer XL version 
1.10 (Leica, Nussloch, Germany). The procedure involved treatment with xylene (2 x7 min), a 
descending alcohol series (100% for 2 min, 100% for 1 min, 94% for 30 sec, 50% for 30 sec), 
and aqua for 30 sec. Antigen demasking was carried out by heating the samples in a microwave 
oven in 1 mM EDTA buffer, pH 8.0 for 2 x 5 minutes at 1000 W and 5 minutes at 700 W. 1.6% 
methanol-peroxidase was used to inhibit endogenous peroxidase activity. For 
immunohistochemistry, specimens were incubated overnight at room temperature with diluted 
(1:100) mouse monoclonal antibody for human cyclin D1 (Novocastra Laboratories Ltd., 
Newcastle, UK). A peroxidase-conjugated secondary antibody was used to detect binding of the 
primary antibody using the Vectastain Elite ABC kit (Vector Laboratories, Inc.). Finally, the 
    
 
36 
sections were counterstained with hematoxylin and embedded using a standard protocol. A 
positive and negative control was included in each experiment. The positive control was a 
mantle cell lymphoma known to overexpress cyclin D1, and the negative control was the test 
specimen without the antibody incubation. Samples with 40% or more immunopositive cells 
were classified as cyclin D1 positive; those with less than 40% of the cells expressing cyclin D1 
were classified as negative. In the latter samples, the proportion of stained cells never exceeded 
10%. 
 
7.2.5. Single strand conformation polymorphisms (SSCP) (Study IV) 
 
The primer sequences used for each of the 15 exons of the PPP2R1B gene together with the 
corresponding annealing temperatures are listed in Study IV. The reactions were carried out in a 
50 µl reaction volume containing 100 ng of genomic DNA, 1 x PCR buffer (Perkin Elmer, 
Norwalk, CT, USA), 250 µM dNTPs (Amersham Pharmacia Biotech), 0.6 µM reverse and 
forward primers, and 2U of AmpliTaq LD (Perkin Elmer). In the reaction for exon 8, the 
concentrations of the forward and reverse primers were 0.5 µM and 1 µM, respectively. The 
concentrations of MgCl2 and DMSO in the reaction mix were as follows: 1mM MgCl2 for exons 
4, 5, 7, 13 and 15; 2.5 mM MgCl2 for exons 3, 9, 10, 11 and 12; 1.5 mM MgCl2 for exons 2, 6 
and 14, and 6% DMSO for exon 1. The PCR profile for all exons except 1and 8 was as follows: 
10 min at 95 °C; then 40 cycles of: 95 °C for 45 s; corresponding annealing temperature for 30 
s; and 72 °C for 15 s; and a final extension of 6 min at 72 °C. The profile for exon 1 was 10 min 
at 95 °C; 40 cycles of: 95 °C for 1 min; 60 °C for 1 min; and 72 °C for 1 min; and a final 
extension of 10 min at 72 °C. The profile for exon 8 was 10 min at 95 °C; 40 cycles of: 95 °C 
for 1 min; 57 °C for 1 min; and 72 °C for 1 min; with a final extension of 10 min at 72 °C.  
After PCR, equal volumes of each reaction mixture and denaturing loading buffer (95% 
formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanole) were mixed, 
denatured for 5 min at 95 °C and loaded onto a 0.4 mm x 30 cm x 45 cm gel. Electrophoresis 
was carried out using gels containing 0.5 x mutation detection enhancement gel solution (FMC 
Bioproduct, Rockland, ME, USA) and 1 x TBE buffer. The gels were run at 3-6 W overnight 
and were then stained with silver according to the standard procedures. 
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7.2.6. Genomic polymerase chain reactions and sequence analysis (Study IV) 
 
PPP2R1B gene fragments showing aberrant bands in the PCR-SSCP analysis were further 
sequenced to confirm the results. The PCR-products were purified using the QIAquick PCR 
purification kit (QIAGEN, Valencia, CA, USA). DNA-concentrations were estimated using a 
fluorometer (DNA fluorometer model TKO 100, Hoefer Biotech, San Francisco, CA, USA) and 
UV spectrophotometry (Ultrospec III, Pharmacia Biotech, Uppsala, Sweden). One hundred 
nanograms of the product were sequenced using an automated sequencing machine. The 
sequencing reactions were performed using either ABI PRISM Dye Terminator or ABI PRISM 
dRhodamine cycle sequencing kits (Perkin-Elmer) according to the manufacturer’s instructions, 
and reactions were run on ABI 373 A or 377 sequencers (Perkin-Elmer), respectively. 
 
7.2.7.    Statistical analysis (Studies I, II and III) 
 
Frequency tables were analyzed using Fisher’s exact test. Differences between two groups in 
parathyroid gland weight, serum parathyroid hormone levels, and serum calcium levels were 
compared using Mann-Whitney’s U-test for non-normal distributions. All P-values are 2-tailed. 
 
8.   RESULTS 
8.1.  DNA copy number changes in thyroid tumors (Studies I and II) 
8.1.1.  Follicular adenoma (Study I) 
 
Twenty-nine follicular adenomas were investigated using CGH. DNA copy number changes 
were found in 14 of them (48%). The most common changes were the gains in chromosomes 7 
(34% of samples), 5 (28%), 12 (24%), 14 (21%), X (17%), 17 (17%), 18 (14%) and 9 (10%). In 
particular, a gain of the entire chromosome 7 was present in all 10 adenomas that displayed one 
or more gains. Only 9 (13%) of the total of 72 changes found in the adenoma samples were 
losses, and they occurred in only 4 (14%) samples, whereas gains were found in 10 (35%) 
samples. On average, there were 2.5 changes per adenoma (median, 1; range, 0 to 12). Gains of 
DNA sequences occurred in 16 different chromosomes, and the gain of a whole chromosome 
was very common (74% of all changes), probably related to trisomy of chromosomes 3, 4, 5, 7, 
9, 10, 12, 13, 14, 16, 17, 18, 19, 20, and X. High level amplifications were not found in our 
adenoma samples.  
In four cases, the only change was the loss of an entire chromosome or chromosomes. These 
losses involved chromosomes 1, 2, 3, 6, 11, 13 and 22. Two of these four follicular adenomas 
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with a chromosome loss were histologically classified as atypical adenomas. A DNA copy 
number gain was not found in any of the five atypical follicular adenomas. 
 
8.1.2.  Follicular carcinoma (Studies I and II) 
 
Altogether 20 follicular carcinomas were studied using CGH. DNA copy number changes were 
detected in 16 tumors (80%). The median number of changes per case among those with 
aberrations was two (range, 0 to 8), and 48 changes were detected in all. Thirteen (65%) of the 
follicular carcinomas had lost chromosomal material. DNA sequence copy number changes 
were observed in eight different chromosomes, 1, 9, 13, 17, 18, 19, 21 and 22. The most 
common loss was of the entire chromosome 22, which was found in seven out of the 20 tumors 
(35%), and in addition, one minimally invasive carcinoma showed deletion at 22q12.3.-qter. 
The loss of the entire chromosome 22 was, therefore, detected in 7 (54%) of the 13 widely 
invasive carcinomas, but in none of the seven minimally invasive carcinomas (P = 0.04). This 
aberration was also significantly more common in older than in younger patients (P = 0.01). 
Four of the patients from whom the follicular carcinoma samples came are known to have died 
from thyroid cancer, and in three of them chromosome 22 had been deleted.  
To confirm the loss of chromosome 22 detected in the CGH analyses, two-color FISH 
was performed on five follicular carcinoma samples which had shown the deletion and on three 
follicular carcinoma samples in which chromosome 22 had not been deleted. In all five samples 
with the deletion, only one hybridization signal for both chromosome 22 specific probes was 
observed in more than 83% of the cells, whereas two signals were found in all three carcinomas 
that did not have the deletion. The CGH results were, therefore, confirmed by FISH. 
Other common losses occurred at 13q21-22 (5 tumors, 25%) and at 1p21-22 (4 tumors, 
20%). The most common gains were at 1q (5 tumors, 25%) and 17q (4 tumors, 20%). High-
level amplifications were rare in follicular carcinoma and were detected in only one tumor, at 
14q11.2-q22 and at 18q12.1-q21. Widely invasive follicular carcinomas exhibited more 
chromosomal changes than the minimally invasive ones (median 2 versus 1, respectively, 
P=0.06). 
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8.1.3.  Papillary carcinoma (Study II) 
 
In papillary carcinoma, DNA copy number changes were rare and were detected in only three 
(12%) of the 26 carcinomas studied. The only aberrations found in papillary carcinoma were 
DNA sequence gains, and these affected five different chromosomes. A gain of DNA sequences 
was detected at 1q23-qter, 5q14-q23.3, 5q23.3.-qter, 7, 17, and 21q22.1-qter (once each). The 
patients with DNA copy number changes were older (all older than 70) than those without 
changes (P=0.01), and tended to have cervical node metastases more often than those with a 
normal CGH profile (P=0.08).  
 
8.1.4.  Medullary carcinoma (Study II) 
 
CGH analysis of 10 medullary carcinomas revealed DNA sequence copy number changes in 
five (50%) of them. These occurred in eight different chromosomes (median of 0.5 
aberration/tumor; range, 0 to 5). Four of the five tumors with copy number changes had 
deletions and one had gains. The most common losses were in chromosomes 3, 13, and 22 
(20%). Other losses were at 1p31.1-p32, 18p or 18q21-qter (once each). Multiple gains 
consisted only of aberrations, and were only present in one case.  
 
8.1.5.  Anaplastic carcinoma (Study II) 
 
Eleven (85%) out of the 13 anaplastic carcinomas studied showed DNA copy number changes 
in the CGH analysis. Altogether 32 changes were detected, but 13 of them were found in one 
tumor. Gains (n = 27) predominated over losses (n = 5). The most frequent gains were at 7p22-
pter (31%), 8q22-qter, and 9q34-qter (both 23%). Loss of chromosome 22 was found in one 
tumor (8%).   
 
8.1.6.  Comparison of DNA copy number changes in thyroid tumors (Studies I and II)  
 
Altogether, 98 thyroid tumors were studied using CGH (Table 2), and a total of 172 DNA copy 
number changes were found (Table 3). The majority (n=127) of changes were gains of genetic 
material, which were found in all the histological types of thyroid tumors, although they were 
rare in the papillary and in the medullary types.  
DNA copy number changes were frequently found in follicular adenomas (48%), follicular 
carcinomas (80%), medullary carcinomas (50%) and anaplastic carcinomas (85%), but only 
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rarely in papillary carcinomas (12%). Deletions were predominant in follicular carcinoma (65% 
of changes) unlike in follicular adenomas (14%) or papillary carcinomas (0%). Gains at 17q 
occurred in both follicular adenomas (17%) and follicular carcinomas (20%). Both deletions 
and gains were found in 25% of follicular and 15% of anaplastic carcinomas, whereas none of 
the papillary and medullary carcinomas had both deletions and gains. Loss of chromosome 22 
was most common finding in follicular carcinoma (7 out of 20, plus one partial deletion), 
whereas this aberration was found in only two (7%) of the adenomas, one of which was an 
atypical adenoma. Loss of chromosome 22 was also found occasionally in medullary and 
anaplastic carcinomas, but none of the papillary carcinomas had this change.  
 
 
Table 3. DNA copy number changes in thyroid neoplasms and parathyroid lesions by the histological type. 
 
 Frequency no. of 
cases/ total (%) 
Number of changes 
found 
 The most common gains and 
losses (percent of cases) 
  Deletions Gains  
Thyroid neoplasms     
  Follicular adenoma 14/29  (48%) 9/29 63/29 +5 (28%), +7 (34%), +12 (24%), 
+14 (21%), +X  and, +17 (17%), 
+18 (14%) 
  Follicular carcinoma 16/20  (80%) 22/20 26/20 +1q (25%), +17q (20%),  
-1p21-p22 (20%), -13q (25%),  
-22 (40%)  
  Papillary carcinoma  3/26  (12%) 0/26 6/26 +5q (8%) 
  Medullary carcinoma  5/10  (50%) 9/10 5/10 -3q, -13, -22 (all 40%)  
  Anaplastic carcinoma 11/13  (85%) 5/13 27/13 +7p22-pter (31%),  +8q22-qter and, 
+9q34-qter (23%) 
     
Parathyroid lesions     
  Primary hyperplasia  4/24  (17%) 6/24 1/24  -11 and, -13 (8%) 
  Adenoma 10/16  (63%) 20/16 9/16 +7 and, -6q, -13q (all 19%),  
-11q (31%), -15 and, -18 (13%)  
 
 
8.2.   Genetic alteration in parathyroid lesions  
8.2.1.  DNA copy number changes in parathyroid hyperplasia and adenoma (Study III)  
 
In general, the pattern of chromosomal changes was similar in parathyroid hyperplasias and 
adenomas (Table 3). However, parathyroid adenomas more often exhibited chromosomal 
changes (10 out of 16, 63%) than parathyroid hyperplasias (4 out of 24, 17%; P = 0.0059). The 
changes were clearly concentrated in particular chromosomal regions in both types of 
parathyroid lesions.  
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In primary hyperplasias, losses (86% of the DNA changes) were more common than gains, and 
they were associated with four different chromosomes, numbers 4, 6, 11 and 13. Losses were 
also predominant in tertiary and MEN1-related hyperplasias. Sequences from chromosomes 11 
were lost in two (8%) of the 24 glands with primary hyperplasia, in one of three glands with 
tertiary hyperplasia, and in all four cases of MEN1-related hyperplasia. Loss of chromosome 13 
was detected in two primarily hyperplastic glands from the same patient, as well as in one case 
of tertiary hyperplasia and in one case of MEN1-related hyperplasia. Other losses occurred at 4q 
(one primary and one tertiary hyperplasia), 6q (one primary and one tertiary hyperplasia), and at 
15q, 18 and X (in one case of MEN1-related hyperplasia). Gains were found in 12q (one 
MEN1-related hyperplasia) and of chromosome 19 (one primary hyperplasia).  
We used CGH to study several glands (2-4) from each of five patients with primary 
hyperplasia. In three of these five patients no DNA copy number changes were present in any of 
the glands. However, in one case in which all four glands were investigated, deletions of 6q14-
qter and 11q14-q23.1 and a gain of chromosome 19 were found in one gland, but there were no 
DNA copy number changes in the other three glands. In another case, deletion of 4q25-q30 and 
loss of chromosome 13 were found in one gland and the loss of chromosome 13 in another 
gland, but no changes were found in the third gland investigated.   
We found as many as 29 DNA copy number changes in the 16 parathyroid adenomas we 
studied. Losses (n=20, 69%), as in the hyperplasias, were again more common than gains (n=9, 
31%). The most frequent loss was that of the entire chromosome 11 or a part of it (in 5 out of 16 
samples, 31%), with 11q22-q24 as the minimal common region. Other common losses were 
found at 6q and at 13q (n=3 for each, 19%), and in two cases (13%) chromosomes 15 and 18 
were partially or completely lost. The most common gain was of chromosome 7 (n=3). High-
level amplifications were detected in only one case, at 7q21-q35, 8p12-p22 and 8q21.2-qter.     
No copy number alterations were detected in any of the five histologically normal 
parathyroid glands included in this study. 
 
8.2.2. Deletions at 11q (Study III) 
 
CGH revealed a regional copy number loss at 11q23. To validate the CGH findings, we chose 
18 parathyroid lesions for FISH analysis using the YAC 755b11 (11q23) clone as the probe. In 
all four cases in which the CGH analysis had revealed a deletion of 11q, the FISH analysis 
found only one hybridization signal in >75% of the cells using YAC 755b11 (1.6 Mb) as the 
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probe. Moreover, only one hybridization signal was detected, using the YAC953e4 clone that 
hybridizes to 11p13, in two of these cases in which the CGH analysis had revealed a deletion of 
11p. In the other cases, four hyperplasias and 10 adenomas, in which the CGH analyses had 
revealed no detectable changes in chromosome 11, we found two signals for both YAC 755b11 
and 953e4 in >80% of the cells. 
We used FISH to investigate DNA copy numbers of the MEN1 gene, mapping to 11q13, 
in nine of the parathyroid lesions in which the CGH analysis had revealed no deletions at 
11q23. This analysis showed two hybridization signals in >85% of the cells analyzed in each 
case. In three other cases with a deletion at 11q23 identified using CGH, both alleles of MEN1 
were found to be present in the  FISH analysis. Hence, the results obtained by FISH were fully 
concordant with those of CGH.  
 
8.2.3.  Associations between DNA copy number changes and serum calcium and parathyroid 
hormone levels and gland weight (Study III) 
 
Clinical features of primary parathyroid hyperplasia patients with DNA copy number changes  
and those without such changes were compared. No differences between these two groups were 
detected in parathyroid gland weight, serum calcium level, or serum parathyroid hormone level 
as measured at diagnosis (P=0.23, 0.47, and 0.64, respectively). Similarly, no differences in 
gland weight or serum calcium or parathyroid hormone levels were found in parathyroid 
adenoma patients with or without a DNA copy number change (P=0.19, 0.11, and 0.18, 
respectively).  
 
8.2.4. Cyclin D1 protein expression in parathyroid lesions (Study III) 
 
A total of 47 parathyroid glands was examined for cyclin D1 overexpression using 
immunohistochemistry. All 27 parathyroid hyperplasias studied were negative for cyclin D1, 
whereas six (40%) out of the 15 adenomas tested were cyclin D1 positive (P=0.001). None of 
the five normal parathyroid tissue samples showed cyclin D1 overexpression. Thirteen (81%) of 
the 16 adenoma samples showed either chromosomal loss or cyclin D1 overexpression, and 10 
(63%) showed either specific deletion of 11q23 or cyclin D1 overexpression. 
One of the five adenomas with an 11q deletion did show positive staining for cyclin D1. 
However, the partial deletion in 11q in this adenoma was located at 11q22-q23, whereas the 
cyclin D1/PRAD1 oncogene is located at 11q13, so none of the cyclin D1 overexpressing 
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adenomas showed a loss of 11q13. We were unable to detect statistical differences in serum 
calcium or parathyroid hormone concentrations between patients with cyclin D1 overexpressing 
adenoma and those with cyclin D1 negative adenoma (P=0.34 and 0.69, respectively), and no 
difference in parathyroid gland weight was found between these two groups (p=0.75). 
  
8.2.5.   Alterations in the PPP2R1B gene (Study IV)  
   
We screened 19 parathyroid lesions (four primary, one MEN1-related and two tertiary 
hyperplasias and 12 adenomas) using PCR-SSCP analysis and direct sequencing for PPP2R1B 
gene mutations. SSCP-analysis was performed for all 15 exons of the PPP2R1B gene. This 
analysis showed that one of the five adenomas with deletion of 11q23, as detected by CGH, 
showed an aberrant band shift in exon 3 of PPP2R1B. DNA sequencing of this sample revealed 
a G>A  transition (GGC>GAC) in codon 90, which results in the substitution of glycine (Gly) to 
aspartic acid (Asp). We also analyzed a tissue biopsy taken during colon endoscopy to 
investigate the cause of chronic constipation in this patient. We detected the same G>A 
substitution in the colon biopsy, which was histologically normal, indicating that this change 
represented a germline gene alteration. In the normal colon tissue both of the alleles were  
present, but in the parathyroid adenoma the common glycine encoding allele (GGC) was lost. 
To validate the SSCP results, we also sequenced exon 3 in six other cases (one hyperplasia and 
five adenomas), but no alterations were found.  
 
 
 
 
 
 
 
 
 
 
    
 
44 
9.  DISCUSSION 
9.1.     Methodological aspects of the comparative genomic hybridization technique 
 
Comparative genomic hybridization (CGH) is a molecular cytogenetic technique for screening 
the whole genome for altered chromosomal regions in solid tumors in one hybridization 
experiment. CGH has been widely applied in tumor pathology, and knowledge of chromosomal 
aberrations in solid tumors has expanded rapidly. A large number of CGH studies have already 
been published (reviewed by Knuutila et al., 1998; reviewed by Knuutila et al., 1999). In 
contrast to other methods, such as traditional cytogenetic, multicolor fluorescence in situ 
hybridization (mFISH) or spectral karyotyping, CGH can detect chromosomal aberrations 
without needing to limit the analysis to dividing cells. Instead, CGH relies on the isolation of 
DNA from fresh or paraffin-embedded tumor samples, and then labeling and hybridizing this 
DNA to normal metaphase chromosome preparations (Kallioniemi et al., 1994; Isola et al., 
1994). 
The main advantage of CGH over traditional cytogenetic techniques is the avoidance of 
the possible genetic alterations that can arise during long-term cell culture and of the problems 
associated with low mitotic rates. Conventional cytogenetic analysis is also unable to reveal the 
genetic composition of unidentified marker chromosomes, heterogenously staining regions and 
douple minutes that can be detected by CGH. Fluorescence in situ hybridization (FISH) 
techniques are highly useful in the analysis of interphase nuclei and metaphase preparations of 
malignant cells, but a significant limitation is that FISH can only provide information from one 
or a few specific genes, chromosomes or chromosomal regions at a time. However, balanced 
translocations, inversions, small deletions and polyploidizations are not detectable using CGH. 
Some problematic areas of the genome which contain highly repetitive sequences, such as the 
pericentromeric and the heterochromatic regions (centromeres and telomeres), cannot be 
analyzed reliably using CGH (Kallioniemi et al., 1994). Other chromosomal regions which may 
occasionally be problematic in CGH analysis are 1p32-pter, 16p, 19 and 22 (Kallioniemi et a., 
1994). Thus, it is often useful to use both CGH and FISH, because they complement each other.  
The sensitivity of CGH depends on the size of the affected region and magnitude of the 
copy number change. DNA copy number changes of 10-20 Mb in size have been reliably 
detected using CGH (Kallioniemi et al., 1994; Bentz et al., 1998). However, changes smaller 
than this can only be detected if the sequence is highly amplified, such as the 5- to 10-fold 
amplification of a region 1 Mb in length (Forozan et al., 1997). Sensitivity is also dependant on 
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the proportion of cancer cells present in the tissue sample analyzed. Cancer cells must 
contribute at least 50% of the total DNA content of the sample for reliable detection of DNA 
copy number changes, and this may be problematic in tumors characterized by karyotypic 
heterogeneity and abundant filtration by normal cells. Several modifications and improvements 
have been reported in CGH methodology (Speicher et al., 1993; Kuukasjärvi et al., 1997; El-
Rifai et al., 1997; Karhu et al., 1999; Klein et al., 1999). For example, if only a limited amount 
of DNA is available the DOP-PCR may be a useful technique. It allows amplification of the 
whole genomic DNA of the test sample and the DOP-PCR product can then be used in CGH 
(Speicher et al., 1993; Kuukasjärvi et al., 1997). However, there are methodological difficulties 
with this technique, such as contaminated DOP-PCR batches and false-positive aberrations in 
CGH.  
CGH is especially suitable for studying chromosomal changes in solid tumors, which 
can lead to the identification of important genes related to cancer genesis in the amplified or 
deleted regions (Visakorpi et al., 1995; Anzick et al., 1997; Hemminki et al., 1997). The CGH 
method can also be used to detect chromosomal imbalances when monitoring tumor evolution 
and progression, and it has diagnostic potential for the classification and definition of different 
tumor types (Heselmeyer et al., 1996; Kjellman et al., 1996; Gronwald et al., 1997; Hyytinen et 
al., 1997; Kuukasjärvi et al., 1997; Tapper et al., 1997; Björqkvist et al., 1998; Sarlomo-Rikala 
et al., 1998).  
 
9.2.  Chromosomal gains and losses in thyroid neoplasms (Studies I and II) 
 
Follicular thyroid adenomas often contain numerical chromosomal abnormalities, chromosome 
gains being the most characteristic finding (Study I). DNA copy number changes were frequent 
in follicular adenomas (14/29; 48%). The most characteristic changes were gains of the entire 
chromosomes 5, 7, 12, 14, 18 and X. Most of these changes have been previously detected by 
conventional cytogenetic analysis (van den Berg et al., 1990; Antonini et al., 1993; Roque et al., 
1993a; Heim et al., 1995; Belge et al., 1998; Mazzucchelli et al., 2000). Our results showed that 
DNA copy number changes were frequent in follicular adenomas and that they have a tendency 
to cluster in certain chromosomal regions. Our findings are comparable with two other CGH 
studies (Fig 3.), which showed frequent DNA copy number changes (50% to 86%) in follicular 
thyroid adenomas (Tallini et al., 1999; Frisk et al., 1999). However, Frisk and coworkers (1999) 
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found that although half of the adenomas showed alterations, the number of changes per tumor 
was low.  
We analyzed a total of 20 follicular thyroid carcinomas in Studies I and II, and found 
that DNA copy number losses were more prominent than gains, unlike in adenomas. We 
detected loss of the entire chromosome 22 or part of it in 40% of the follicular carcinomas. This 
aberration was the most frequent single aberration, and has not previously been pinpointed as 
one of the most frequent chromosomal abnormalities in follicular carcinoma. A loss of genetic 
material in chromosome 22 is not restricted to follicular thyroid carcinoma; it has also been 
detected in other tumor types, such as meningioma and mesothelioma (Tonk et al., 1992; 
Björkqvist et al., 1997). A possible candidate for an important tumor suppressor gene located in 
chromosome 22 is the neurofibromatosis type 2 (NF2) gene at 22q12 (Ruttledge et al., 1994), 
but there are probably many other similar genes, such as the putative tumor suppressor gene 
distal to NF2 described by Schofield and coworkers in 1996.  
Loss of chromosome 22 was found more frequently in widely invasive than in minimally 
invasive follicular carcinomas, and three of the four patients who died of follicular carcinoma 
had this change. This finding might suggest that deletion of chromosome 22 is involved in the 
malignant progression of follicular carcinoma. However, the number of carcinoma samples 
analyzed so far is too small to allow any firm conclusions, and further studies are needed to find 
out whether deletion of chromosome 22 is associated with poor outcome in follicular thyroid 
carcinoma. Our finding is well in line with a FISH study where the loss of chromosome 22 was 
detected in five out of 14 (36%) cases of the widely invasive oncocytic follicular carcinomas 
(Mazzucchelli et al., 2000). However, they also found this alteration in three out of 11 (27%) 
minimally invasive carcinomas.   
Apart from loss of chromosome 22, many other DNA copy number changes may also be 
important in the pathogenesis of follicular carcinoma. We detected loss of genetic material in 
chromosome 13 in 25% of the cases, with the minimum common region of deletion being 
13q21-q22. Deletion of 13q has also been found in various other neoplasms, such as 
retinoblastoma, prostate cancer, renal cancer, breast cancer, small-cell lung carcinoma and 
parathyroid carcinoma (Cryns et al., 1994; Dotzenrath et al., 1996; Mitelman et al., 1997; 
Petersen et al., 1997; Tirkkonen et al., 1998). Several tumor suppressor genes are found in13q, 
such as RB1 (13q14.3), BRCA2 (13q12), and ING1 (13q34). However, all of these genes reside 
outside our minimal common region. Loss at 1p is common in several cancers (Mertens et al., 
1997), and we found this aberration in 20% of follicular carcinomas. Recently, TP73 has been 
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mapped to 1p36. Its tumor protein, p73, is known to share considerable homology with the 
tumor suppressor protein p53, which suggests that TP73 might be a candidate for an important 
tumor suppressor gene located in 1p (Jost et al., 1997). The 1p36 region is frequently deleted in 
neuroblastomas as well as in other tumors (Kaghad et al., 1997).  
The most recurrent gains in follicular carcinoma were detected at 1q (25%) and 17q 
(20%). We found that the loss at 1p occurred simultaneously with a gain at 1q in 15% of the 
cases. Gain of 1q is also common in other tumors, e.g. in mesothelioma, large B-cell lymphoma, 
and bladder cancer (Kallioniemi et al., 1995; Monni et al., 1996; Björkqvist et al., 1997). 
However, the candidate genes have yet to be identified (Knuutila et al., 1998). ERBB2 (avian 
erythroblastic leukemia viral oncogene homolog 2) is one of the known proto-oncogenes 
located at 17q12. Frisk and coworkers (1999) only found infrequent CGH alterations in their 
series of 13 follicular carcinomas (Fig 3.), and they also found no difference in the frequency of 
alterations between minimally and widely invasive carcinomas in this small series. However, 
gains of chromosomes 7 and 17 were also characteristic findings in their series. In another CGH 
study DNA copy number changes were frequently found in widely invasive oncocytic follicular 
carcinomas, but the study consisted of only four cases (Tallini et al., 1999).  
DNA copy number changes occurred infrequently (12%) in our series of papillary 
carcinomas. This finding is well in line with previous conventional cytogenetic studies, where 
papillary carcinomas are characterized by relatively simple cytogenetic changes (Bondeson et 
al., 1989; Jenkins et al., 1990; Teyssier et al., 1990; Herrmann ME et al., 1991; Antonini et al., 
1992; Sozzi et al., 1992a; Herrmann and Lalley, 1992; Roque et al., 1995; Lehmann et al., 1997; 
Roque et al., 2001). However, CGH cannot detect balanced rearrangements such as inversion of 
the RET oncogene, which is reported to occur frequently in papillary carcinoma (Jenkins et al., 
1990; Grieco et al., 1990; Herrmann MA et al., 1991; Herrmann ME et al., 1991; Sozzi et al., 
1992a; Nikiforov et al., 1997). The only DNA copy number changes we found were gains of 
genetic material at 1q23-qter, 5q14-q23.3, 5q23.3-qter and 21q22.1-qter, and of the whole of 
chromosomes 7 and 17.  
The CGH abnormalities detected in our series of papillary carcinomas were associated 
with old age. Although chromosomal changes may be associated with a general increase in 
genomic instability with age, this finding is well in line with earlier findings. Papillary 
carcinomas in elderly patients have been found to be associated with more nuclear irregularity, a 
slightly increased mitotic rate and an increased probability of DNA aneuploidy as determined by 
DNA flow cytometry, than carcinomas in young patients. Older individuals with papillary 
    
 
48 
carcinoma are more likely to die of their thyroid cancer than patients who are younger than 40 at 
the time of the same diagnosis (Franssila, 1971; Joensuu et al., 1986). Overall, the DNA copy 
number changes we detected in papillary thyroid carcinoma are quite  similar than those 
reported in other CGH studies (Chen et al., 1998; Singh et al., 2000; Kjellman et al., 2001). In 
these studies the most frequent gains were observed at 1q, 2p, 5q, 6q, 9q, 13q, 17q, 22q and X, 
and the most frequent losses involved 1p, 9q, 17, 19 and 22. However, these studies have 
reported a varying frequency of alterations in papillary carcinoma (Fig 3.), ranging from 48% to 
as high as 88% (Chen et al., 1998; Singh et al., 2000; Kjellman et al., 2001). The differences in 
the frequency of DNA copy number changes found in papillary carcinoma between the various 
studies may be caused by differences in study populations, the size of tumors chosen for 
analysis, and/or the presence of intratumoral heterogeneity. In addition, the frequency of the 
various molecular abnormalities may differ significantly between geographical regions. Singh 
and coworkers (2000) claimed to have identified two genetically unique groups of patients with 
papillary thyroid cancer using CGH. One group had no detectable aberrations, whereas the other 
group had a recurrent pattern of similarly located aberrations. In the study of Kjellman and 
coworkers (2001) gains and losses occurred at approximately the same frequency (54% versus 
46%). These authors also suggested that gain of 1q and loss of 9q21.3-q32 are associated with 
an unfavorable prognosis in papillary thyroid carcinoma. 
Anaplastic thyroid carcinoma is one of the most aggressive human cancers and one 
might expect, therefore, to find numerous and chaotic genetic changes in this tumor type. The 
number of cases of anaplastic carcinoma studied using CGH is limited (Fig 3.), and the genetic 
background of this tumor is poorly understood (Mark et al., 1987; Jenkins et al., 1990; Zedenius 
et al., 1996; Roque et al., 1998b; Ward et al., 1998; Kitamura et al., 2000; Wilkens et al., 2000). 
A few previous studies using conventional cytogenetic analysis have suggested that some 
anaplastic carcinomas have complex karyotypes that include signs of gene amplification with 
double minute chromosomes and homogeneously staining regions (Mark et al., 1987; Jenkins et 
al., 1990; Roque et al., 1998b). However, CGH analyses of anaplastic thyroid carcinoma have 
detected no high-level amplifications to support this suggestion (Hemmer et al., 1999; Wilkens 
et al., 2000). We found DNA copy number changes in most (85%) of our anaplastic thyroid 
carcinoma samples. Gains of genetic material were more frequent than losses. The most 
common changes were gains at 7p22-pter (31%), 8q22-qter (23%), and 9q34-qter (23%). 
Possible candidate proto-oncogenes which are located in these regions are the platelet-derived 
growth factor-α  gene (7p), the CMYC gene (8q), and the ABL and VAV2 genes (9q). Our 
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results agree with those of Wilkens and coworkers (2000), who carried out CGH analysis on 
nine primary anaplastic carcinomas and found aberrations in eight cases (89%) (Wilkens et., 
2000). They suggested that aberrations in 5p, 8p and 8q may play an important role in the 
development of anaplastic carcinoma. The relatively small number of tumor samples analyzed 
may explain the somewhat variable findings, and many of the DNA copy number changes may 
be secondary to tumor progression. The small numbers of anaplastic carcinomas analyzed by 
CGH prevent any firm conclusions being drawn (Hemmer et al., 1999; Wilkens et al., 2000).  
In our series of 10 medullary thyroid carcinomas, CGH analysis revealed DNA copy 
number changes in 50% of the cases. Losses were more common than gains (Table 3; Fig 3.). 
Previous cytogenetic analyses have identified only a few sporadic medullary carcinomas with 
abnormal karyotypes (Tanaka et al., 1987; Wurster-Hill et al., 1990) Our results are in line with 
these studies in which the most consistent finding was a normal modal number of chromosomes 
with a marked tendency to random hypodiploidy (Wurster-Hill et al., 1990). Hypodiploidy has 
also been found in cell lines established from medullary carcinoma (Tanaka et al., 1987). We 
found genetic losses were most common in chromosomes 3, 13, and 22 (each in 20% of the 
cases studied). In agreement with our results, Frisk and coworkers (2001) detected DNA copy 
number changes in 14 out of 24 of the medullary carcinomas using CGH analysis, and we both 
found that losses of genetic material from chromosomes 3 and 13 were among the most frequent 
findings. Frisk and coworkers (2001) suggested that medullary carcinomas with aggressive 
clinical features show a greater than average number of genetic alterations. They also found 
frequent gains at 19q, 19p, 11cen-q12 and 22q. The differences between this study and ours 
may reflect differences between the tumors analyzed, the small numbers of cases studied, tumor 
heterogeneity, technical factors, and the fact that some of the changes detected might be 
secondary to tumor progression. In addition, chromosomes 19 and 22 may be particularly 
sensitive to artifacts in a CGH analysis, leading to false ratio values (Kallioniemi et al., 1994).  
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Figure 3. Number of chromosomal gains and losses detected in different histologic types of thyroid tumors in 
different studies by using CGH. A. Follicular adenoma  B. Follicular carcinoma C. Papillary carcinoma D. 
Anaplastic carcinoma E. Medullary carcinoma. 
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9.3.  Comparison of chromosomal alterations between histological subtypes in thyroid 
neoplasms (Studies I and II) 
 
There is still only limited evidence for the so-called adenoma-carcinoma sequence of 
development for the thyroid follicular cell. The differential diagnosis between follicular thyroid 
adenoma and carcinoma is sometimes difficult, because some follicular adenomas bear a close 
morphological resemblance to follicular carcinoma. The main difference is invasion through the 
capsule or into blood vessels by the carcinoma (Franssila 1997). Some recent data support the 
multistep pathway model (normal thyroid - goiter- adenoma- follicular carcinoma) for the 
tumorigenesis of some thyroid tumors (Roque et al., 1999). However, there are also studies that 
support the hypothesis that follicular thyroid adenomas and carcinomas develop along separate 
pathways (Zedenius et al., 1996; Dahia et al., 1997; Marsh et al., 1997; Frisk et al., 1999; Yeh et 
al., 1999). At first sight our CGH results might conform better to the latter hypothesis, since the 
DNA copy number changes of most follicular adenomas and carcinomas differ greatly from 
each other. However, in four follicular adenomas the only aberration detected was a loss of an 
entire chromosome or chromosomes, and in two of them the lost chromosome was 22, which is 
frequently lost in follicular carcinoma. In two of the five atypical adenomas studied losses were 
found, and in one of these it was chromosome 22 that had been lost. Taken together, these 
findings suggest that some follicular adenomas, including atypical adenomas, may have a 
common genetic origin with follicular carcinomas. It needs to be born in mind that follicular 
adenomas are common tumors in the general population whereas follicular carcinomas are rare, 
and if follicular carcinomas develop from a pre-existing adenoma, such adenomas form only a 
small fraction of all follicular adenomas. 
Some reports have suggested that papillary carcinomas originate de novo from the 
normal follicular epithelium, whereas the genesis of follicular carcinomas may follow the 
sequential normal – adenoma – carcinoma multistep model (Wynford-Thomas and Williams 
1989). The findings from loss of heterozygosity studies have suggested that papillary thyroid 
carcinoma and follicular carcinoma develop along distinct pathogenic pathways (Learoyd et al. 
2000). A meta-analysis of LOH studies has also confirmed high rates of LOH in follicular 
cancers (Table 1), and low rates of LOH in papillary thyroid carcinomas and follicular 
adenomas (Ward et al., 1998). This finding suggests a fundamental differences in the 
pathogenesis of these two tumor types and is supported by the more recent finding of LOH at 7q 
in follicular and anaplastic thyroid cancers but not in papillary carcinomas (Trovato et al., 
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1999). The results presented here suggest that follicular carcinomas display more chromosomal 
alterations than papillary carcinomas. Although both of these types of thyroid carcinoma are 
associated with a generally favorable prognosis, their molecular genetic origin may be widely 
different. As many as 80% of follicular carcinomas and only 12% of papillary carcinomas 
showed DNA copy number changes in the present series. Moreover, deletions were much more 
frequent in follicular than in papillary carcinoma (65% vs. 0%, respectively). In particular, loss 
of chromosome 22 was common in follicular carcinoma, absent in papillary carcinoma, but 
occurred occasionally in medullary and anaplastic carcinomas. All in all, CGH analyses 
revealed striking differences between follicular and papillary carcinomas, which further support  
the concept that follicular and papillary carcinomas are different entities, and suggests that their 
genetic evolution is also different. 
The DNA copy number changes in anaplastic carcinoma also seem to be very different 
from those seen in follicular and papillary carcinomas. Although DNA copy number changes 
were demonstrated in most anaplastic carcinomas (85%), the number of deletions was, 
somewhat surprisingly, lower than in follicular carcinomas (23% vs. 65%, respectively). 
Therefore, the relative frequency of DNA copy number changes, as detected in CGH analysis, 
does not seem to be directly associated with clinical aggressiveness, at least when different 
histological types of cancer are compared with each other. This hypothesis is supported by 
Study I, where CGH analysis revealed large gains of genetic material in many histologically and 
clinically benign thyroid adenomas (Hemmer et al., 1998). 
In summary, the results presented in this thesis suggest that the different histological 
subtypes of thyroid neoplasia may evolve and/or progress along have distinct molecular genetic 
pathways. However, the numbers of thyroid tumors investigated using CGH are still small, and 
these findings need to confirmed in future studies to allow firmer conclusions to be drawn.  
  
9.4. Chromosomal gains and losses in parathyroid lesions, and comparison of DNA 
copy number changes between parathyroid hyperplasia and adenoma (Study III)  
 
The main difference between primary parathyroid hyperplasias and adenomas in the present 
series was that DNA copy number changes occurred relatively infrequently in primary 
parathyroid hyperplasias (17%) compared with parathyroid adenomas (63%). However, the 
DNA copy number changes in both types of lesion were clearly associated with certain 
chromosomal regions, most often being seen in chromosomes 11, then in chromosomes 6 and 
13. Our study revealed more losses of DNA sequences than gains, which is in line with previous 
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cytogenetic studies (Friedman et al., 1989, 1992; Thakker et al., 1989; Cryns et al., 1995; 
Tahara et al., 1996; Farnebo et al., 1997, 1999; Teh et al., 1998; Agarwal et al., 1998; 
Palanisamy et al., 1998; Dwight et al., 2000). Apart from our study, however, no other CGH 
study of primary parathyroid hyperplasias has so far been published.  
The most frequent change detected in our analysis was deletion of the entire 
chromosome 11 or a part of it. This change was present in 8% of primary hyperplasias and in 
31% of adenomas with a common minimum deleted region of 11q22-q23. We also confirmed 
deletion of 11q23.1 or its absence using FISH. Our CGH results on parathyroid adenomas are in 
accordance with those of previous CGH studies (Fig 4), in which the frequency of loss at 11q 
varied between 34% and 50% (Agarwal et al., 1998; Palanisamy et al., 1998; Farnebo et al., 
1999). The loss of the whole of chromosome 11 was present in all four MEN1-related cases in 
our series, where somatic loss of the remaining MEN1 allele may have resulted in the 
development of the hyperplasia. However, the number of secondary, tertiary and MEN-related 
hyperplasias we studied was too small to allow for meaningful conclusions, although the CGH 
findings were in line with those obtained using FISH. Importantly, all three cases in which we 
detected deletion of 11q23 in both CGH and FISH analyses, and that were further investigated 
using FISH to determine the MEN1 allele copy number, had both MEN1 alleles located at 11q13 
present, suggesting that 11q23 might contain an important suppressor gene that is distinct from 
MEN1. A similar suggestion was also made earlier by Evans and coworkers (1998). Deletion at 
11q22-q24 also frequently occurs in other types of tumors, including ovarian, colorectal and 
breast carcinoma, and mantle cell lymphoma (Foulkes et al., 1993; Keldysh et al., 1993; 
Kerangueven et al., 1997; Monni et al., 1998; Knuutila et al., 1999). All these observations 
together support the hypothesis that an important tumor suppressor gene distinct from MEN1 
may be located within 11q22-q24. One such candidate gene, located at 11q23, is the recently 
cloned PPP2R1B, which encodes for the β isoform of the A subunit of the serine/threorine 
protein phosphatase 2A (PP2A). Mutations of PPP2R1B have been reported in human colon 
and lung cancers, chronic lymphocytic leukemia and mantle cell lymphoma, and in some breast 
carcinomas (Wang et al., 1998, 1999; Calin et al., 2000; Takagi et al., 2000; Zhu et al., 2001). It 
has been suggested that the PPP2R1B gene product suppresses tumor development through its 
roles in cell cycle regulation and cellular growth control. Other possible putative tumor 
suppressor genes located within this region are the ATM  (ataxia-telangiectasia mutated) and 
PGL1 genes. ATM has a role in cell cycle checkpoint control, genome surveillance and cellular 
defense against oxidative stress (Rotman et al., 1997). PGL1 may be involved in the genesis of 
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paragangliomas (Baysal et al., 1998), a rare disorder presenting most often as tumors of the 
head and neck. Of note is the observation that parathyroid adenomas and thyroid carcinomas 
may occur concurrently with jugulotympanic and carotid body paragangliomas (Revac et al., 
1971). 
 
 
Figure 4. The comparison of the frequencies of the most common gains and losses in parathyroid adenomas from 
four CGH studies. A. Palanisavy et al., 1998; n=53 B. Agarwal et al., 1998; n=10 C.  Farnebo et al., 1999; n=26 
D. Study III; n=16. 
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(Cryns et al., 1994; Tahara et al., 1996; Dotzenrath et al., 1996; Pearce et al., 1996; Kytölä et 
al., 2000). The minimum common region of loss at 6q was 6q22-q24. Loss at 6q has been 
reported frequently in different types of human cancer, but so far no tumor suppressor gene has 
been identified in this region (Knuutila et al., 1999). However, studies on breast and ovarian 
cancer have implicated the chromosomal regions 6q23-q25 and 6q24-q25 as locations for 
putative tumor suppressor genes (Theile et al., 1996; Wan et al., 1999).  One candidate tumor 
suppressor gene located within 6q24-q25, a region lost in two parathyroid hyperplasias and 
three parathyroid adenomas in our study, is a zinc finger gene called LOT/1/hZAC (Abdollahi et 
al., 1997; Varrault et al., 1998). This gene was cloned in 1997 and reported to display loss of 
expression in human ovarian cancer (Abdollahi et al., 1997), and to exhibit tumor growth 
inhibition functions (Varrault et al., 1998).   
In addition to the above finding, we detected high level amplifications at 7q21-q35, 
8p12-p22 and 8q21.2-qter in one adenoma, which is the first time that such amplifications have 
been described in parathyroid neoplasms. A potent candidate oncogene located at 7q31 is the 
CMET gene, which codes for a transmembrane tyrosine kinase receptor and is the ligand for 
hepatocyte growth factor/ scatter factor. High-level copy number increases at 8q have also been 
detected in many other types of tumor (Knuutila et al., 1998). In solid tumors, a DNA copy 
number change at chromosome arm 8q has been associated with tumor progression (Isola et al., 
1995). In one parathyroid adenoma, we detected a high-level amplification in 8q (8q21.2-qter), 
a region which contains a probable candidate oncogene, CMYC, at 8q24 (Knuutila et al., 1998). 
However, in this oxyphilic adenoma, tumor blood vessel invasion was seen in one small vein, 
which could be interpreted as a sign of carcinoma. As the tumor did not fulfill other criteria of 
malignancy, it was classified as atypical adenoma. The association between this amplification 
and genesis of parathyroid carcinoma requires further study.  
 In summary, our results showed that DNA copy number changes are more frequent in 
parathyroid adenomas than in primary parathyroid hyperplasias, but that they appear to have a 
tendency to cluster in the same chromosomal regions in both types of lesion. The region 11q23 
is frequently lost in parathyroid adenomas and occasionally in parathyroid hyperplasias, and this 
finding suggests that this region may contain one or more tumor suppressor genes. It might, 
therefore, provide a good starting point for further molecular analyses.    
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9.5.  Expression of cyclin D1 and alterations of PPP2R1B suppressor gene in 
parathyroid lesions (Studies III and IV) 
 
Two genetic mechanisms have been described, so far, for the development of parathyroid 
adenomas. They are the activation of the oncogene cyclin D1 (11q13) and the inactivation of the 
MEN1 (11q13) tumor suppressor gene. To date, the only established parathyroid tumor 
oncogene is cyclin D1, which has an important role in the control of cell cycle progression 
through the G1/S checkpoint. In this study, we studied the frequency of cyclin D1 protein 
expression in parathyroid hyperplasias and adenomas using immunohistochemistry. Our results 
revealed cyclin D1 overexpression in 40% of parathyroid adenomas but in none of the 
hyperplasias studied, indicating a clear-cut difference in cyclin D1 expression between 
parathyroid adenomas and hyperplasias based on immunohistochemistry. Frequent 
overexpression of cyclin D1 in adenomas suggests that pericentromeric inversion of 
chromosome 11, which places the PTH gene’s transcriptional regulatory sequences adjacent to 
the cyclin D1 proto-oncogene resulting in inappropriate cyclin D1 overexpression and enhanced 
cell proliferation, is common in parathyroid adenomas but not in hyperplasias. Our results are 
well in line with previous studies where cyclin D1 overexpression has been detected in 20 to 
40% of parathyroid adenomas (Hsi et al., 1996; Tominaga et al., 1999b; Vasef et al., 1999). 
However, there is disagreement between our study and that of Vasef et al., (1999), in which 
cyclin D1 overexpression was also found in 61% of parathyroid hyperplasias. The reason for 
this difference is not known. These authors found that cyclin D1 expression is rarely present 
(6%) in normal parathyroid tissue (Vasef et al., 1999). It is worth noting that we found either 
DNA copy number loss or cyclin D1 overexpression in as much as 81% of parathyroid 
adenomas investigated. This suggests that the pericentromeric inversion of chromosome 11, 
which cannot be detected using CGH, and suppressor gene loss are both important mechanisms 
in the molecular pathogenesis of parathyroid adenomas. Although pericentromeric inversion 
and suppressor gene loss are different molecular genetic mechanisms, they might both favor cell 
proliferation over apoptosis, and result in the genesis of morphologically similar parathyroid 
adenomas. Based on the results to date, these two mechanisms may explain the molecular 
pathogenesis of the majority of parathyroid adenomas.  
We found that 11q22-q24 was frequently deleted in parathyroid lesions (Study III), suggesting 
that this chromosomal region may harbor a putative suppressor gene with an important role in 
parathyroid tumorigenesis, such as the PPP2R1B gene. Therefore, we further investigated this 
potential suppressor gene for the presence of mutations. Six parathyroid hyperplasias and 12 
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adenomas were chosen for analysis using PCR-based single strand conformation polymorphism 
(SSCP) and direct sequencing. One adenoma case showed a germline G-A transition (GGC-
GAC) in codon 90, in which glycine was changed to aspartic acid. Wang and coworkers (1998) 
found the same alteration in lung and colon cancers, and also suggested that it might be a 
germline mutation. Campbell and Manolitsas (1999) demonstrated the alteration in ovarian 
cancers, but they found no significant difference in the frequency of this change in ovarian 
cancer patients and non-cancer controls representing the general population, so they suggested 
that it represents a non-pathological variant. Their finding is also supported by another ovarian 
study (Wu et al., 1999). Taken together, all these findings suggest that mutations in the 
PPP2R1B gene seem not to play a significant role in the molecular genesis of parathyroid 
lesions, and that the glycine to aspartic acid change is a fairly common polymorphism of the 
gene. Other putative tumor suppressor gene or genes located in the 11q23 region may be more 
closely associated with the pathogenesis of parathyroid hyperplasia and adenoma. It should be 
taken into account that the SSCP method, as with all other mutation screening methods, may 
miss some mutations. Due to the limited information available on the intron sequences at the 
Genebank, only some of the PCR primers designed for SSCP analysis allowed splice sites to be 
investigated.    
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10. SUMMARY AND CONCLUSIONS 
 
The aim of this thesis was to investigate DNA sequence copy number changes in tumors of two 
endocrine organs, the thyroid and the parathyroid, using comparative genomic hybridization 
(CGH), and to investigate cyclin D1 overexpression in parathyroid lesions. In Study III, the 
deletion of 11q22-q24 was frequently detected in parathyroid lesions using CGH, suggesting 
that this chromosomal region may harbor a putative suppressor gene, such as the PPP2R1B 
gene, with a possible role in parathyroid tumorigenesis. We, therefore, further examined this 
potential suppressor gene for possible mutations.     
CGH revealed that DNA copy number changes are frequent in follicular adenomas, and 
in follicular, medullary and anaplastic carcinomas of thyroid, but rare in papillary thyroid 
carcinoma. The DNA copy number changes in follicular adenomas and carcinomas were 
different. Gains of the entire chromosomes 5, 7, 12, 14, 17, 18 and X were common in follicular 
thyroid adenomas, whereas losses of chromosomal material were detected more frequently in 
follicular carcinomas. Losses occurred most frequently in follicular carcinoma in chromosomes 
1, 13 and 22, whereas gains were most frequently located in 1q and 17q. Loss of chromosome 
22 was particularly common in follicular carcinoma, where it was found in almost half of the 
patients (40%), but we also detected this change in some of the medullary and anaplastic 
carcinomas studied. Loss of chromosome 22 was found more often in widely invasive type than 
minimally invasive type of follicular carcinoma, suggesting that there might be association 
between loss of chromosome 22 and the widely invasive histological type. It was associated also 
with old age at presentation. However, association of chromosome 22 loss with prognosis 
requires further studies. Unlike in follicular carcinoma, gains of the genetic material were the 
only CGH findings in papillary carcinoma, and only in elderly patients. In medullary carcinoma 
DNA copy number changes were detected in 50% (5/10) of the cases. Losses of genetic material 
were more common than gains, the most frequent being losses of chromosomes 3, 13 and 22 
(two losses each). Most of the anaplastic carcinomas (85%) showed DNA copy number 
changes. Chromosomal gains predominated over losses, but the number of deletions was lower 
than in follicular carcinomas (23% versus 65%, respectively). Gains occurred most commonly 
in 7p, 8q and 9q, and were found in 23 to 31% of the cases. 
  DNA copy number changes were frequent in parathyroid adenomas (63%) unlike in 
parathyroid hyperplasias (17%). However, the genetic changes affected the same chromosomal 
regions in both hyperplasias and adenomas. Cyclin D1 overexpression was found to be common 
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in adenomas (40%), whereas none of the parathyroid hyperplasias showed cyclin D1 
overexpression. Either DNA copy number loss or cyclin D1 overexpression was present in as 
many as 81% of the adenomas, which suggests that pericentromeric inversion of chromosome 
11 leading to cyclin D1 overexpression and suppressor gene loss are important underlying 
mechanisms in the molecular pathogenesis of parathyroid adenomas. In parathyroid adenomas 
deletion at 11q23 was frequent (31%) and this change was also detected in some of parathyroid 
hyperplasias (8%). This finding suggests that a putative tumor suppressor gene at 11q23 may 
play an important role in the pathogenesis parathyroid lesions. 
This hypothesis was examined further by studying the putative role of the recently 
identified candidate suppressor gene PPP2R1B located at 11q23 in the molecular pathogenesis 
of parathyroid adenomas and hyperplasias. We used single-strand conformation polymorphism 
(SSCP) and direct sequencing to detect PPP2R1B gene mutations. However, only one adenoma 
case showed germline G-A transition (GGC-GAC) in codon 90, which changes glycine to 
aspartic acid in the protein product of the gene. These data suggest that somatic mutations in 
PPP2R1B gene are not common in parathyroid adenomas or hyperplasias, and seem not to play 
a significant role in the pathogenesis of these lesions. Therefore, the 11q23 region may harbor 
other suppressor gene or genes, which are more important in pathogenesis of parathyroid 
lesions.  
At first sight the present CGH findings differ strikingly between follicular adenoma and 
carcinoma of thyroid, and might argue against the presence of an adenoma-carcinoma sequence 
in the pathogenesis of follicular thyroid neoplasms. However, we detected loss of genetic 
material in four adenomas, and in two of them the loss included loss of chromosome 22, which 
is common in follicular carcinoma. Because follicular adenomas are much more common in the 
general population than follicular carcinomas, the present findings are not contradictory to the 
hypothesis that pathogenesis of many follicular carcinomas, may follow a sequential normal 
tissue-adenoma-carcinoma multistep pathway. Comparison of DNA copy number profiles 
between follicular and papillary carcinoma revealed large differences between these histological 
types of thyroid carcinoma, providing further evidence to the generally accepted view that these 
subtypes of thyroid carcinoma are different entities, and suggests that papillary and follicular 
thyroid carcinomas may follow different genetic pathways in carcinogenesis and/or tumor 
progression. DNA copy number changes were also different in anaplastic carcinoma as 
compared to follicular or papillary carcinomas. Based on these CGH data, it can be concluded 
that different histological subtypes of thyroid tumors have distinct DNA copy number profiles. 
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The finding that large changes in cellular DNA content may be present in adenomas of 
the endocrine organs is not new, but our results show that follicular adenomas of the thyroid and 
parathyroid adenomas display distinct DNA copy number changes. Interestingly, parathyroid 
hyperplasias and adenomas showed more DNA copy number changes in CGH analysis than 
papillary thyroid carcinomas, suggesting that the molecular genetic mechanisms that lead to 
benign endocrine tumors may be complex and variable, and that the association between the 
amount of DNA lost or gained and malignant potential may be poor in different histological 
types of tumors.   
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